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Abstract 
 
Because of the complexity of the cytokine network, an individual cytokine measurement 
may be difficult to interpret or may provide insufficient information to inform 
conclusions.  Multiplexing technology, which allows for the simultaneous measurement 
of multiple analytes, has advanced the study of cytokine secretion patterns.  However, if 
cytokines are to be measured and used to make conclusions on research studies, we must 
understand the variability around the measurement and the potential for errors associated 
with testing.  Method validation procedures generate data that reflect assay performance 
and identify the inherent measurement uncertainty, allowing data to be accurately 
interpreted.  This study included the design and performance of a multiplex assay 
validation assessment for the simultaneous measurement of 23 cytokines in non-human 
primate (NHP) serum.  The validation included analysis of serum samples from 36 
healthy cynomolgus macaques in order to determine if the method could be used to detect 
cytokine concentrations in healthy NHP.  Although sensitivity and precision data were 
generally acceptable, recovery and linearity data were highly variable.  Of the 23 
cytokines tested, 11 met acceptance criteria, 5 were marginal and 7 were rejected.  The 
ability of the method to detect cytokine concentrations was demonstrated and cytokine 
concentration ranges were presented for 15 cytokines as measured in serum from healthy 
cynomolgus macaques.  If the validation studies had not been performed, false 
conclusions could be made (overestimated or underestimated cytokine values) 
contributing to errors within the Total Testing Process.  It would be appropriate to 
continue to evaluate the impact of pre-analytical error (e.g. storage time and temperature, 
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blood collection steps) on the measurement of cytokines in serum from cynomolgus 
macaques.  Because this work demonstrates significant variability among measurements 
within and between animals, other important next steps include the description of typical 
variation levels within and between animals, followed by the generation of appropriate 
(population- or subject-based) reference intervals for healthy animals.  It is clear after 
performing this validation study, that clinical and research investment in multi-analyte 
methods is not warranted without demonstration of method validity for each analyte of 
interest. 
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 Introduction 
Cytokines 
Cytokines are a complex network of regulatory proteins that contribute to cell growth, 
differentiation and signaling and they play important roles in embryonic development [1], 
normal physiological function, immune response and tissue repair.  As of 2012 there 
were about 250 proteins categorized as cytokines and it is likely that more will be 
discovered [2].  Cytokines are secreted from white blood cells and various other cells 
(e.g. thymic, endothelial) throughout the body at concentrations ranging from ng/mL to 
pg/mL.  These minute levels of cytokines often act in an autocrine or paracrine fashion, 
exerting their effects locally, rather than systemically.  Cytokine actions may be 
inhibitory or stimulatory.  They can be redundant, i.e. two distinct cytokines may act on 
the same cell to produce the same effect, or they may be pleiotropic, i.e. one cytokine 
may act on multiple cells to produce different effects [3].  The action a cytokine exerts 
depends on the environment where it is released, as some cytokines display synergistic or 
antagonistic effects depending on the presence of other cytokines [4].  This complexity 
makes it difficult to predict the effects of individual or associated cytokines.    
 
The current cytokine field developed as a merging of four independent areas of research 
associated with lymphokines, interferons, colony-stimulating factors and growth factors.  
Lymphokines are cytokines secreted by lymphocytes; they were first discovered in the 
1960s when it was observed that lymphocyte-secreted products could affect the growth 
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and function of other leukocytes [5].  Interferons were first recognized for their ability to 
act in an antiviral manner in the 1950s, and later it was determined that they were also 
able to affect cell growth and differentiation [5].  Colony-stimulating factors are proteins 
that stimulate differentiation of hematopoietic stem cells but can also affect fully 
differentiated cells.  Finally, as the name suggests, growth factors are necessary for the 
normal growth and development of non-hematopoietic cells [5] and they can aid in 
chemotaxis, cell proliferation and synthesis of other cytokines.  In 1965 it was noted that 
an antiviral agent was secreted by a lymphocyte which would have made the antiviral 
agent both an interferon and a lymphokine. As similar connections were observed, the 
distinctions between these four areas began to break down. At the time, the term 
lymphokine was commonly applied to many regulatory proteins, even when they were 
not secreted by lymphocytes, so the term “cytokine” was proposed in 1974 to encompass 
the expanding field [6].  Since 1960, this field has grown every year until 2011; a search 
of “cytokines,” as the medical subject heading in PubMed shows one result for 1960 
followed by a steady increase to almost 29,000 results for 2012.  This same search 
resulted in about 27,000 hits for 2013, suggesting that research in the cytokine field may 
have reached a plateau and is waning.  
 
 Cytokines have been referred to as the ‘hormones of the immune system’ because 
cytokines, like hormones, function as biological messengers.  However, there are 
differences.  The majority of cytokines are not constitutively produced, but rather are 
stimulated in the event of a host challenge (presence of tumor cells, bacterial or viral 
2 
 
 
infection, tissue injury) [5].  In addition, cytokines typically function in an autocrine or 
paracrine manner, exerting their effects locally, often making them undetectable in 
circulation.  Many hormones function in an endocrine manner and most can be detected 
systemically.  Despite these differences, it is clear that  cytokines and hormones are 
becoming more associated by mechanism and function, and some molecules classically 
considered hormones, like growth hormone, prolactin and leptin, are considered by some 
to be cytokines, in spite of their names or historical categorization [7].   Examples of 
cytokine/endocrine connectivity  include: the cytokine interleukin- (IL) 1beta induces 
adrenocorticotropic hormone (ACTH) release [8], ACTH has been shown to induce the 
expression of IL-18 from adrenal cortex cells [9] and the pituitary has been shown to be 
important to immune function [10].  The hormone resistin is secreted mainly by 
peripheral blood mononuclear cells [11] and is involved in inflammation [12], endowing 
it with cytokine-like properties.   
 
In this thesis, a commercial analytical method for simultaneously determining the 
concentration of 23 individual cytokines in NHP serum was evaluated to determine if it 
met pre-established method validation acceptance criteria.  These 23 cytokines are of 
interest because they are involved in inflammatory and immune response pathways and, 
when taken together, can signify changes in immune status.  A brief overview of each of 
the 23 cytokines analyzed in this thesis is provided in Appendix A  
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Methods for Measuring Cytokines 
Cytokines are often measured in samples from healthy and diseased laboratory animals to 
evaluate their potential as biomarkers for dysfunction.  Like hormones, cytokines are 
frequently measured in serum or plasma using  enzyme-linked immunosorbent assays 
(ELISA) [13–17] .  This method provides acceptable sensitivity, rapid turn-around time, 
safety and convenience (radio-isotopes are not required) and affordability.  The ELISA 
method has been used for cytokine analysis in samples from cows [18], rats [19], dogs 
[20], humans and cynomolgus macaques [21].      
 
ELISA components differ by manufacturer, and results may be affected by antibody 
characteristics and specific manufacturer reagents [22].  Technical competency is also 
important to obtaining accurate results.  Results determined using ELISA may differ 
when compared to results generated using radioimmunoassay (RIA) or 
chemiluminescence.  Therefore, it can be challenging to compare results generated by 
different people using different methods at different facilities on different sample 
populations.  Recognizing and understanding this variability is critical for interpreting 
(and comparing) data appropriately.    
 
One way to establish the accuracy, reliability and comparability of data generated under 
varying conditions is to evaluate method validation characteristics determined to identify 
measurement uncertainty.  When a method validation data summary is provided with the 
research results it is possible to understand the inherent error around the measurement 
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and a comparison of methods becomes much more straightforward.  Method validation 
procedures for ELISA include the demonstration of analytical sensitivity, linearity, 
precision (intra- and inter-assay) and accuracy (the ability to recover spiked analyte).  For 
example, in one report, an ELISA method for use with samples from human and 
cynomolgus macaques, was demonstrated to be accurate for the measurement of 
cytokines based on the demonstration of dilutional linearity, precision of <20% 
coefficient of variation (CV) and accuracy in the 80-120% range [116].   
 
Other techniques used less frequently in the past to measure cytokine concentration in 
serum or plasma have included radioimmunoassay [23], chemiluminescence [24],  gene 
expression assay [25] and two multiplexing techniques, sandwich ELISA multiplex (e.g. 
SearchLight) [26] and bead based multiplex (e.g. Luminex) [27].  Multiplexing 
technologies feature the simultaneous measurement of concentrations of multiple 
analytes within a single sample.  This technology is of interest for use in monitoring 
cytokines because individual cytokine results are frequently considered in relation to 
other cytokines as a profile of associated values.  Due to the complexity of the cytokine 
network, an individual cytokine measurement may be difficult to interpret or may provide 
insufficient information to inform conclusions.  For these reasons, cytokine panels are 
one of the most popular commercial multiplexed panels available and they are being used 
by researchers in both human and animal medicine [28–31].   
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Multiplexing has clear advantages over traditional ELISA methods.  It provides the 
opportunity to save time, sample volume and reagents because many analytes can be 
measured at once, commonly using only 25 µL of sample.  Cytokine multiplex methods 
provide improved sensitivity, generating results in the pg/ml range, rather than the ng/ml 
range achieved using the ELISA method; this is especially important when measuring 
systemic cytokines as the circulating levels are usually very low even if relatively high 
levels are present in a specific microenvironment [32].   
 
Bead based multiplexing technology is based on the principles of flow cytometry, 
whereby particles are suspended in a fluid and flow past a laser used to discriminate 
among differences [33].  This technology uses microspheres, known as “beads,” which 
are filled with a mixture of red and infrared fluorophores (a chemiluminescent 
compound) to create a spectral signature unique to each analyte.  The outer surface of 
each bead is coated with antibodies specific for one analyte.  After antibody capture, a 
reporter (streptavidin phycoerythrin) is added to the sample wells which will allow for 
luminescence of all the bound analyte.  The beads flow through the instrument single-file 
and are first detected by a red laser (635 nm) which excites the internal dyes and 
classifies the bead by individual analyte.  The beads continue past a green laser (532 nm) 
which excites the reporter attached to the analyte and the mean fluorescence intensity 
(MFI) for each bead is measured and averaged with all other beads for the same analyte.  
The beads initially developed for this technology were polystyrene-based and a specific 
filter-bottom 96-well plate had to be used in conjunction with a vacuum system for liquid 
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removal.  However, magnetic-bead technologies which consist of beads with a 
superparamagnetic core have been recently developed. The new magnetic bead kits can 
be used with a hand-held magnet which temporarily attaches to the bottom of a solid 96-
well plate, keeping the beads adhered to the bottom of the wells while the plate is 
washed.  Magnetic beads provide for more effective washing/separation steps which 
result in less bead loss and improved replicate measurements as indicted by lower CV 
between replicates.  With the use of magnetic beads in multiplex kits now becoming the 
norm, many companies are eliminating polystyrene bead based kits.  Beads developed by 
the Luminex Corporation are the most commonly used for multiplexing kits by various 
manufacturers and require a special Luminex instrument for detection; other non-
Luminex (cytometric bead array) kits can be used with a traditional flow cytometer.   
 
There are, of course, challenges in manufacturing and effectively using multiplex 
immunoassays.  Reagent optimization will affect the quality of a multiplex assay and the 
production of the specific beads that present the individual antibodies can ultimately 
affect sample measurements.  For example, the purity of the beads (free of biological 
contamination), and strength of the bond between the antibody and the bead surface can 
influence the dynamics of the assay.  It has also been reported that 10% to 32% of 
measurement variability could be due to variations in bead diameter during 
manufacturing [34].  In addition, the pH and ionic strength of buffers can affect protein 
structure, thus changing the ability of the protein analyte to bind to the appropriate 
antibody.  Optimizing a kit with so many diverse analytes presents challenges as it can be 
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difficult to select appropriate buffers that will not alter any of the associated analytes 
present in the multiplex panel [35].  Likewise the optimal incubation times, temperatures 
and reagent concentrations must be appropriate for all analytes in the panel.  Multiplexing 
is also more prone to cross-reactivity since multiple antibodies to several, and possibly 
similar, analytes are present within a single test well [36].  For example, IL-2 and IL-15 
are structurally similar cytokines [37] and since all reactions occur in the same well 
during a multiplexed assay, the antibody for IL-2 may also bind to IL-15 molecules, 
causing the concentration results for IL-2 to be inaccurately elevated.  Additional 
variability in results may occur as a result of the rapid degradation of cytokines in blood 
and the need for highly sensitive assays in order to measure cytokines that are present 
(and perhaps biologically relevant) at very low concentrations (picomole range).   
 
Many cytokines are not expected to be present in elevated concentrations in healthy 
animals (because they are inflammatory and/or involved in the immune response 
pathways), therefore, representative data reflecting normal patterns of secretion are not 
available. As a result, some of the test validation procedures are harder to plan and 
implement (for example if endogenous samples with variable concentrations are not 
available to combine, it is difficult to create serum pools that can be used as quality 
control samples that cover the critical range of the standard curve.)  
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An understanding of the uncertainty that is due to the method as well as the inherent 
variability within a healthy animal is required before changes in cytokine concentration 
can be considered significant or informative during dysfunction or disease. 
  
Comparison of Methods: ELISA and Multiplex 
Because previously published cytokine data were generated using ELISA, multiplex 
technology has been compared to ELISA methods in order to assess whether the methods 
provide similar results with similar conclusions.  In 2003, a comparison between a 15-
cytokine multiplex assay developed in-house and several individual ELISAs for each of 
the same 15 cytokines was reported [36].   The multiplex assay was constructed with 
reagents from 6 different manufacturers and the 13 ELISAs came from 5 manufacturers.  
The cytokine measurements were found to be strongly correlated by method (correlation 
coefficients ranging from 0.75 to 0.99).  In contrast, Liu et al. reported poor correlation 
between multiplex and ELISA methods when comparing measurement of human IL-6, 
IL-8 and TNFα (correlation coefficients ranging from 0.107 to 0.318)  [38].  In 2004, 
Khan et al. compared four different manufacturers multiplex kits (5-plex) to a single 
ELISA designed for use with serum from humans.  They found the concentrations 
obtained from the ELISA were only similar to the results from the multiplex kit from the 
same manufacturer, presumably because the same antibody was used in both kits [39].  In 
2006, a National Institute of Health (NIH) study group evaluated the performance of 
ELISAs in comparison to multiplexed assays by performing a comprehensive literature 
review.  Not surprisingly, they reported that the highest correlations were found when 
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comparing kits from the same manufacturer, as these share a common, proprietary 
antibody pair [40].  This group also reported that even in the cases of good correlation, 
the absolute concentrations observed form the two methods generally differ, while the 
trends remain the same.  A study published in 2004 by the Eli Lilly Research 
Laboratories supports this finding [41].  That group also reported acceptable correlation 
(concordance correlation coefficient = 85%) between an in-house human five-plex 
cytokine multiplex assay and ELISAs for one of the cytokines (IL-6).  They noted, 
however, that the multiplex results were, on average, 2.36-fold higher than the ELISA 
results.  Other investigators have compared the two different methods with mixed results:  
Richens et al. reported good correlation (R2 values 0.98-0.99) between multiplex kits and 
an ELISA for the measurement of  IL-8  in human blood/serum [42].   Dossus et al. 
reported  highly variable correlations (correlation coefficients from 0.37 – 0.92) when 
comparing measured concentrations from a multiplex assay to results from ELISA kits 
for the measurement of IL-6, TNFα, IL-1β, IL-1ra, CRP and sCD40L in paired serum 
and plasma samples from human patients [43].   
 
This variability in results generated using different methodologies is not unusual and 
several factors may contribute to it.  For instance, proprietary antibodies, reagents and 
standard matrices from different manufacturers, as well as different sample handling 
conditions, may influence results and contribute to the range of correlation reported.  In 
addition, Breen et al. have reported that even the same method may generate different 
results when performed in different locations [44].  In that study, four different labs used 
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the same three human cytokine multiplex assays to measure paired sets of 18 serum and 
plasma samples.  Although the observed concentrations showed similar trends between 
labs, the absolute results obtained, even when using the same kits, were highly 
significantly different (P < 0.001) for all kits.  The inconsistent correlation between the 
two methods discussed above should be considered when selecting multiplex 
technologies for cytokine concentration measurement because it is clear that results 
cannot always be related to previous data collected using a different analytical method.  
Investigators need to consider sources of variability and error and establish strategies to 
account for the influence of these factors.  One way to account for this variability and 
potential error is to consider ‘the total testing process, TTP’. 
 
The Total Testing Process 
George Lundberg first introduced the concept of the TTP in 1981 when he outlined a 
series of processes, starting with the clinical question under consideration by the 
clinician, progressing to specific test selection, sample collection, transport to the 
laboratory, analysis, reporting back to the clinician, and final interpretation and decision 
making by the clinician [45].  Lundberg identified the phases associated with these 
processes as pre-analytical, analytical and post-analytical.  Not surprisingly, there are 
opportunities for error to occur at each phase.  Some errors can occur in all phases (e.g. 
transcription error) while others are unique to the phase of work being performed.  The 
potential for error to occur during the pre-analytical, analytical and post-analytical phases 
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is present in any laboratory or research investigation that involves sample collection, 
analysis and interpretation of data resulting from analytical methods.   
 
Pre-analytical errors are those that occur prior to performing the analytical test in the 
laboratory.  They may occur as a result of inappropriate test selection, sample collection, 
sample handling, sample delivery or receiving within the laboratory.  For example, some 
lithium heparin blood collection tubes were found to contain endotoxin which caused IL-
1β and IL-6 to be stimulated [46].  Other examples of pre-analytical errors that may affect 
cytokine measurement include the time elapsed between blood collection and 
centrifugation [47], specimen storage time and temperature, and the choice of blood 
collection tube (plasma vs. serum) [22].   
 
Analytical errors are those that occur at the time the analytical procedure is being 
performed.  Some analytical errors can be reduced by establishing and adhering to 
standard operating procedures; such errors may include using improper reagents, cross-
contamination during sampling, using incorrect procedures and equipment malfunction.  
A critical procedure for mitigating analytical error is to plan and perform a method 
validation strategy to identify the error routinely present within the method.  Additional 
examples of analytical errors include the use of an antibody that is not specific for the 
analyte being tested or the presence of interfering molecules in the sample matrix (such 
as autoantibodies or binding proteins).   
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Lastly, post-analytical errors can also affect data reliability.  Examples of post-analytical 
errors include data upload error, incorrect data analysis, data transcription error, use of 
inappropriate reference intervals, and inappropriate interpretation of results.   
 
 The potential for, and frequency of, errors throughout the TTP have been monitored in 
clinical and diagnostic laboratories for both human and veterinary medicine. In both 
human and veterinary diagnostic laboratories, the majority of errors occur in the pre-
analytical phase (46-77% of total errors), followed in frequency by the post-analytical 
phase (7-46%).  The lowest error rate occurs during the analytical phase of the TTP (7-
21%) [48], [49].  While this is encouraging to analysts, it is important to realize that the 
analytical errors, while less frequent, will likely have the largest negative impact on 
patient care.  
 
The frequency of errors in the analytical phase is low primarily because technologies and 
equipment have been standardized, quality control procedures have been incorporated 
into analytical procedures, and equipment and personnel management systems exist to 
improve consistency and reliability within laboratories.  Many service (but few research) 
laboratories incorporate quality assurance (QA) programs which monitor laboratory error 
as a way to ensure continuous improvement.  These programs integrate document control 
processes (documentation of and adherence to specific procedures), and reagent, 
equipment and personnel management (reagent inventories, equipment maintenance and 
calibration records, and training and competency review and documentation).  In 
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addition, the potential for analytical errors is reduced by a adhering to a defined Quality 
Control (QC) strategy (tracking and trending of QC data) to verify method performance 
over time as a requirement for method validation to establish the reliability and accuracy 
(‘fit for purpose’) of laboratory methods.   
 
Unfortunately, an understanding of the TTP and the associated potential for errors using 
analytical methods is frequently overlooked in research.  For instance, most published 
studies that provide cytokine concentration data and interpretation do not include data 
describing the validation parameters of the method.  For example, a group from the 
Harvard Medical School recently used an ELISA to measure human IL-2 and IL-15 in 
samples from cynomolgus macaques, but they do not mention how they (or others) 
evaluated the assay before use [50].  Similarly, investigators from Japan recently 
analyzed IL-2 and IFNγ in samples from cynomolgus macaques using both an ELISA 
and a Millipore multiplex kit.  Data were not presented to demonstrate the reliability of 
either method [51].  In 2009, investigators submitted serum from cynomolgus macaques 
to a commercial testing service for the measurement of 5 cytokines using the Linco 
multiplex technique. [52].  It is likely that Linco had performed validation studies; 
however, validation data are not summarized or referenced for the reader.  It cannot be 
assumed that a commercial method has been fully validated unless the data are presented 
for review within their kit insert or as part of a publication. Without such information, it 
is difficult to establish the reliability of the data as presented.   
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The intent of validation studies is to ensure a test is “fit for purpose” [53],  meaning that 
experimental validation data must prove the assay performance characteristics are 
acceptable for its intended purpose.  The intended purpose of an assay can vary based on 
individual study goals, for instance analytical data may be used to establish diagnostic 
cut-off values for disease surveillance, generate reference intervals, or establish normal or 
abnormal patterns of secretion.  Important decisions are made based on interpretation of 
small changes in laboratory data (for example, research inclusion and exclusion criteria, 
and clinical and diagnostic cut offs).  Therefore it is imperative to understand the 
potential for error around a given measurement and to describe how the accuracy and 
reliability of those measurements have been determined.   
 
In veterinary medicine and research, commercially available assay kits designed for use 
for human diagnostic testing are frequently used to analyze samples from other species.   
In these cases, it is especially important to evaluate the method to make sure that the 
analytic characteristics of the assay are not affected by species differences such as matrix 
variability.  The matrix of the blood contains different proteins and these proteins will 
vary by species; this variability creates the potential for interference (and subsequent 
error) with assay methodology.  
 
An increasing appreciation for the importance of validation data may be forthcoming. 
The US National Institutes of Health (NIH) are considering strategies that include 
additional requirements for experimental validations within grant applications to address 
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the recent and consistent findings that many published results cannot be replicated [54].  
Research proposals that include clearly described validation strategies may be seen as 
more competitive than those that do not address method reliability and consistency.   
 
Multiplexed Human Cytokine Validations 
Validation reports supporting the reliability of methods for the measurement of cytokines 
in NHP serum are rare.  However, previous studies on the validation of human cytokine 
multiplex assays have been published and show variable results.  The Eli Lilly study 
mentioned previously reported acceptable results for their in-house, human, five-plex 
cytokine assay (IL-1β, TNFα, IL-6, IL-8 and IL-10) with inter-assay precision <25% and 
recoveries of 83% - 125%, for all cytokines [41].  A study published in 2008 compared 
the accuracy of three commercially available human cytokine panels and found that 21%, 
67% and 78% of samples tested for accuracy (from BioRad, R&D Systems and Linco 
respectively) met their acceptance criteria (70% - 130% of expected values) [55].  
Prabhakar et al reported that five of six cytokines tested for accuracy (using a Linco 
multiplex kit) fell within their acceptance range of 80% - 120%, with only TNFα failing 
to meet this criterion [56].  Another study from 2008 assessed the reproducibility of a 
Millipore human cytokine assay and found inter-assay precision (n=3) to range from 18% 
to 44% for ten cytokines [3], while Prabhakar et al reported inter-assay precision of 
<25% for all six cytokines tested and intra-assay precision ranging from 9-21% (n=5) 
[56].  In 2009 Chowdhury, Williams and Johnson published a study including the 
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validation of a 7-plex human cytokine multiplex kit from Biosource.  In that study intra-
assay precision was below 20% (n=10) for all seven cytokines and intra-assay precision 
was found to be highly variable with a range from 3% to 80%.  In the same study, 
accuracy ranges (percent of expected to observed concentrations in spiked samples) were 
found between 38% and 84% [57].  Although this study resulted in highly variable 
results, the authors concluded it was still a valid method after considering several factors 
(limit of detection, precision, accuracy) and the tradeoffs between assay efficiency and 
accuracy.  The examples above show the degree of variability possible among validation 
results, independent of manufacturer (both in-house and commercially available are 
represented), location, or institution (academic, government and industry are 
represented).  In addition to the range of results reported in these publications, an array of 
various acceptance criteria and validation methods were also presented.   
 
Validation Strategy 
A validation protocol is planned to evaluate the routine error around a measurement [58].  
Two types of error can be considered when planning assay validation procedures: 1. 
measurement error, or the variability around a measurement; 2. method error, or the 
limitations of the method.  Sensitivity and precision determinations will identify 
measurement error and the assessment of linearity and accuracy will identify method 
error.  A specificity study, to understand the ability to differentiate analytes in the 
presence of other (possibly similar) components expected in the sample, also helps define 
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the method error.  Understanding these errors, and the limits they infer, can prevent 
incorrect data interpretation and the associated negative effects on research conclusions, 
clinical trials and patient therapies.   
 
One of the first steps in defining a validation protocol is to identify the acceptance criteria 
the method must meet in order to be approved as being ‘fit for purpose’.  These criteria 
should be established before beginning the method evaluation to minimize bias and to 
avoid the tendency to fit the criteria to the generated data [53].  The acceptance criteria 
may be based on previous data using other well characterized or ‘gold standard’ methods.   
 
In 2013, the United States Food and Drug Administration (FDA) released an updated 
comprehensive draft guidance document describing steps and recommendations for 
acceptance criteria for the validation of ligand-binding assays [59].  According to this 
document, the following seven parameters may be included in a full validation of an 
assay: sensitivity, precision, accuracy, recovery, selectivity (specificity), reproducibility, 
and stability of analyte (robustness).  The FDA defines sensitivity as “the lowest analyte 
concentration that can be measured with acceptable accuracy and precision.”  The 
variability around these very low measurements is expected to be greater than at other 
points along the standard curve and it therefore gives slightly more relaxed acceptance 
criteria.  For example, this guidance suggests that all standards should be within 20% of 
their expected concentrations except at the lower limit of quantitation (LLOQ), where 
25% is acceptable.  The second parameter, precision, is the “closeness of individual 
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measures of an analyte when the procedure is applied repeatedly to multiple aliquots of a 
single homogeneous volume of biological matrix.”  The recommendation is to perform at 
least five determinations per concentration and a minimum of three concentrations in the 
expected range of sample concentrations, with acceptance levels of 20% CV or less, 
except at the LLOQ when 25% CV is acceptable.  Precision assessment should be 
performed both within and between assays.  As part of the between-assay precision 
evaluation, incurred sample reanalysis should be performed.  To do so, a selected subset 
of samples (i.e. in biological matrix and not QC pools created in buffer) should be 
analyzed on separate runs on different days to support precision and accuracy findings.  
The next parameter, accuracy, is the degree of closeness of the observed value to a 
“known true value under prescribed conditions.”  Obtaining a sample of known value 
(such as a traceable standard) can be difficult when working in non-human species and 
the FDA guidance suggests confirmation with a validated reference method such as liquid 
chromatography-mass spectrometry (LC-MS), if possible.  It is recommended that 
accuracy be evaluated the same way as precision but with the use of a known-true 
(traceable to a standard) sample.  The next validation parameter to be tested is recovery 
and it is the “the measured concentration relative to the known amount added to the 
matrix.”  Although the guidance document only recommends that recovery be performed 
in ligand-binding assays that use sample extraction, when using a known-true sample, it 
may also serve as an accuracy assessment experiment.  The fifth parameter is 
selectivity/specificity which is described as “the ability of the bioanalytical method to 
measure and differentiate the analytes in the presence of components that may be 
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expected to be present.  These could include metabolites, impurities, degradants, or 
matrix components.”  Selectivity/ specificity addresses two issues of possible 
interference: 1) from substances structurally similar to the analyte of interest, and 2) from 
matrix effects.  To understand interference, the structurally similar substances should be 
added in (or ‘spiked’) at known concentrations, and measured to assess agreement to the 
known-true value; when possible, this should be confirmed with a validated reference 
method (like LC-MS).  Matrix effects may be studied three ways: 1) by linearity 
 (parallelism) whereby a dilution series from a sample is compared to a dilution series of 
standards, 2) by comparing the standard curve in buffer to the standard curve in 
biological fluids and 3) by determining the ‘non-specific binding’ of the assay.  Non-
specific binding refers to the amount of signal (radioactivity, fluorescence, luminescence, 
etc.; used to determine analyte concentration in the sample) that is inherent to the test and 
is not specific to antibody binding.  For example, trace amounts of radioactivity will 
adsorb to the inner walls of tubes that do not contain sample or antibody, and could affect 
the result of a radioimmunoassay, if not accounted for.  Linearity assessments are also 
important if a sample with high concentrations must be diluted to be measured accurately.  
In those instances, not only is the analyte of interest being diluted but so are all of the 
possible interfering proteins in the matrix, which could result in increased binding of 
analyte and misleadingly high results [60].  The next parameter, reproducibility, is the 
“precision between two laboratories” but it also “represents precision of the method 
under the same operating conditions over a short period of time.”  Reproducibility can be 
evaluated by comparing validation results between two or more laboratories performing 
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the same protocol, or by a single lab repeatedly measuring the same quality control (QC) 
or study sample.  In-house QC samples are prepared by pooling previously-tested 
samples of similar concentrations and establishing lab-specific acceptance ranges 
(commonly the mean ± two standard deviations) by testing these QC in each assay to 
verify that the method is working as expected.  The final parameter, robustness, is an 
assessment of “the chemical stability of an analyte in a given matrix under specific 
conditions for given time intervals,” the sample results should be within 15% of expected 
concentrations.  Recommended analyses for robustness may include assessing 
freeze/thaw cycles, bench-top handling conditions, long-term storage, stock solution in 
different states or different buffers, and processed sample stability (time to analysis), if 
applicable.   
 
The FDA guidance document is meant to provide best practice recommendations and all 
of the described steps are not always required to consider an assay validated.  For 
instance, the authors suggest that for exploratory methods, less validation (perhaps only a 
single assay to determine the intra-assay precision and accuracy) may be sufficient [59].  
However, this document recommends that a full validation be implemented when a new 
bioanalytical method is being established. 
 
The multiplex method for measuring the concentration of multiple cytokines in a single 
sample creates an obvious complexity for planning validation protocols.  The FDA 
guidance document states that “samples involving multiple analytes should not be 
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rejected based on the data from one analyte failing the acceptance criteria.” This 
approach will become important as the cytokine multiplex method is assessed in this 
thesis.  
 
Thesis Introduction 
The goal of this thesis was to evaluate the performance of Millipore’s Milliplex MAP 
Non-Human Primate (NHP) magnetic cytokine multiplex assay kit (catalog number 
PCYTMG-40K-PX23) to determine if it is valid or ‘fit for purpose’ for use as a method 
to accurately and reliably measure 23 different cytokines in serum from healthy 
cynomolgus macaques. 
 
Methods verified for use in this species are important. When no suitable alternative 
methods or species are available, the NHP can add translational value because of its 
ability to closely mimic the biological complexity of humans.  When this research was 
initiated, data in the literature that described the analytical validation performance of 
multiplex methods used for cytokine measurements in blood samples from cynomolgus 
macaques were not available.  Previous studies evaluating cytokines in NHP blood using 
multiplex assays have been published [27], [31], [61], [62], however, these studies do not 
provide method validation results.  A recently published paper by He, Narayanan and 
Fort compares the performance of three commercially available multiplex kits in 
cynomolgus macaque serum [63].  However the three kits tested were all polystyrene-
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bead based; one of these kits has already been discontinued (R&D Systems), one is in the 
process of being replaced with a magnetic kit counterpart (Millipore) and the 
manufacturer of the third kit (Life Technologies) plans to transition all multiplex kits to 
magnetic format in the future.  In addition, the study only reported accuracy measured in 
the standards (by comparing manufacturer reported values to observed values) but did not 
assess the accuracy measured in the sample matrix (NHP serum).  Nor did they report 
intra- or inter-assay precision or linearity.  The scarcity of validation data supporting the 
use of this method in the NHP is troubling since cytokine measurements are frequently 
performed and used to inform research strategy, outcomes and direction.     
 
Hypothesis 
The hypothesis of this thesis is that the commercially available Millipore Milliplex NHP 
magnetic cytokine multiplex assay kit is ‘fit for purpose’ as demonstrated by meeting 
pre-established validation criteria for the 23 cytokines being measured in NHP serum.    
 
The specific aims of this study are: 
1. To assess sensitivity, precision, recovery and linearity of a method used to 
measure concentrations of 23 cytokines in one sample aliquot to determine if the 
method meets pre-established validation acceptance criteria. This aim will 
determine if the method is valid, accurate and reliable for the measurement of 
these cytokine concentrations in cynomolgus macaque serum. 
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2. To determine if the assay is suitable for the detection of cytokine concentrations 
in serum from a study population of healthy cynomolgus macaques.   
 
It is not an aim of this study to optimize or influence the production parameters of this 
commercial method.  Instead, we are evaluating its use in our laboratory to define the 
error and limitations of the test and to determine if it is suitable for use in our study 
population.  
24 
 
 Materials and Methods 
Cytokine Assay Kits  
Millipore MILLIPLEX® MAP magnetic bead, premixed 23-plex kits for Non-Human 
Primate Cytokines (cat. no. PCYTMG-40K-PX23) were used according to manufacturer 
instructions.  This is a magnetic bead based assay kit with premixed beads for 23 
cytokines: G-CSG, GM-CSF, IFNγ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-
12/23(p40), IL-13, IL-15, IL-17A, MCP-1, MIP-1α, MIP-1β, sCD40L, TGFα, TNFα, 
VEGF and IL-18.  A standard curve with concentrations ranging from 20,000 pg/mL to 
4.9 pg/mL for IL-4; 50,000 pg/mL to 12.2 pg/mL for IL-10 and IL-18; and 10,000 pg/mL 
to 2.4 pg/mL for the other 20 cytokines was made by serial dilution.  All standards and 
controls were run in triplicate in each assay.  The standards and controls for nine of the 
cytokines (IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-12, IL-13, TNFα and IL-18) were 
recombinant NHP proteins, the standards and controls for the other 14 cytokines were 
human proteins, as shown in Appendix B.  The detecting antibodies for 21 of the 
cytokines were generated against human proteins; detecting antibodies for IL-2 were 
generated against monkey (unspecified) protein while VEGF was generated against 
mouse protein (this data is summarized in Appendix B).  The manufacturer reports “no or 
negligible” cross-reactivity between any of the analytes of the assay panel.  A human 
serum matrix is provided with each assay kit to normalize the assay; this matrix is added 
to wells containing standards and controls which is meant to mimic the NHP matrix of 
the samples.   
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Validation Plan  
Assay sensitivity can be defined two ways:  1) the lower limit of detection (LLOD) which 
is considered the smallest concentration that can be distinguished from zero.  2) The 
lower limit of quantification (LLOQ) which is the smallest concentration that can be 
accurately and precisely tested.  The analysis software used for these studies 
(MILLIPLEX Analyst, version 3.4) determines the LLOD for each individual analyte in 
every assay performed.  LLOD calculations are extrapolated based on the standard curve 
and the background readings for each analyte in each assay.  Therefore the software may 
determine different LLODs for the same analyte over different assays.  Extrapolation was 
done by extending the measured curve concentrations past the limits of the actual points 
measured.  Therefore, to investigate the LLOD for each analyte using actual, measured 
data points, the lowest standard was diluted to 50% with assay buffer and tested in two 
wells in one assay then the lowest standard was diluted to 25% with assay buffer and 
tested in 6 wells in another assay.  The percent of observed concentration was accepted 
(and deemed accurate) if it was between 75% - 125% of the expected concentration [64].  
 
Assay precision was defined as the ability to repeat observed concentrations under the 
same conditions both within a single assay (intra-assay precision) and between assays 
(inter-assay precision).  Intra-assay precision was evaluated at low concentration levels 
and high concentration levels, relative to the standard curve.  To study precision at the 
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lower end of the standard curve, a serum pool was made by combining two samples from 
the same animal, collected four months apart, and spiking with a known amount of kit-
provided standard near the middle of the curve range.  To study precision at higher 
relative concentrations, a second serum pool was made by combining two samples from 
the same animal (but different than the animal used to make the first pool), taken two 
months apart, and spiking with a known amount of kit-provided standard at the highest 
concentration.  Both of these pools were made such that the majority (>90%) of the final 
pool matrix consisted of endogenous NHP serum and the remaining portion consisted of 
assay kit standard.  All samples underwent a freeze-thaw cycle and were then kept at ≤ -
20oC until the date of assay.  The two pools used to study intra-assay precision were 
tested on a single assay plate in 12 wells each.  Inter-assay (between assay) precision was 
determined using four method controls, tested in triplicate, on four separate plates.  Two 
of the four controls used to study inter-assay precision were kit-provided controls, using 
the same lot number throughout the study.  The other two controls were created by a 
mixture of a NHP serum pool (made from the serum of two healthy cynomolgus 
macaques) spiked with a consistent volume of one of the kit-provided controls; see 
Appendix B, Table 12.  The CV (ratio of standard deviation/mean) was calculated from 
the measured concentration of each replicate.  The pre-established acceptance criteria 
selected for a multiplexed method is CV <25% for inter-assay precision and <20% for 
intra-assay precision based on common published  parameters [56], [57], [64]. 
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As described above, accuracy and recovery are similar, with the major difference being 
the use of a “known-true” source for comparison.  Although the standards provided with 
the assay kit are considered a “known-true” source, a confirmatory analysis (for example, 
HPLC) was not performed.  Therefore, the analyses performed for this validation strategy 
are considered recovery and not accuracy.  Recovery is then defined as the degree of 
closeness to the known true value.  Recovery was measured as the percent of observed 
sample concentration relative to the expected concentration in a sample spiked with a 
known analyte concentration.  Samples used to establish the recovery of the method were 
created by measuring cytokine concentrations in two NHP serum pools (constructed as 
described above for precision) with and without spiking of known amounts of two kit 
standards, resulting is 6 distinct samples: sample 1 neat; sample 1 + standard 5; sample 1 
+ standard 7; sample 2 neat; sample 2 + standard 5; sample 2 + standard 7; see Table 1.  
Each of these 6 samples was measured in triplicate and this entire procedure was repeated 
in 6 additional individual animals (for a total of 8 animals) over 3 assays.  Each spiked 
sample was constructed such that the majority (75%) of each sample consisted of 
endogenous NHP serum and the remainder of kit standard.  Recovery was calculated as a 
percent of observed to expected concentrations.  See Table 2 for a summary of spiking 
concentrations and an example of calculations for a single cytokine (IL-15).  For the 
multiplexed method, acceptance criteria for recovery were set to be 75 – 125%  of 
expected values based on common parameters used by researchers in the field for this 
method [56], [57], [64].   
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Table 1: An example of how samples were constructed from 2 of the 8 animals used in recovery 
studies so that resulting solutions contained 75% endogenous material.  
Sample ID Endogenous Component Formula Testing 
Sample 1 neat Animal # 1 No additions; only serum from Animal # 1 
Tested in 3 wells 
in a single assay 
Sample 1 + 
standard 5 Animal # 1 
60 µL serum from Animal # 1 + 
20 µL standard 5 
Tested in 3 wells 
in a single assay 
Sample 1 + 
standard 7 Animal # 1 
105 µL serum from Animal # 1 
+ 35 µL standard 7 
Tested in 3 wells 
in a single assay 
Sample 2 neat Animal # 2 No additions; only serum from Animal # 2 
Tested in 3 wells 
in a single assay 
Sample 2 + 
standard 5 Animal # 2 
60 µL serum from Animal # 2 + 
20 µL standard 5 
Tested in 3 wells 
in a single assay 
Sample 2 + 
standard 7 Animal # 2 
105 µL serum from Animal # 2 
+ 35 µL standard 7 
Tested in 3 wells 
in a single assay 
 
Table 2: Summary of spiking concentrations and an example of recovery calculations for a single 
cytokine (IL-15; 6 of 8 samples were within acceptable recovery ranges, 75% - 125 %, in this 
case). 
IL-15 
  
Added 
Analyte 
(pg/mL) 
Recovery Average per Animal Result 
Assay #1 
Animal #1 2500 54% 53% Reject 625 53% 
Animal #2 2500 113% 112% Accept 625 111% 
Assay #2 
Animal #3 2500 88% 84% Accept 625 80% 
Animal #4 2500 106% 102% Accept 625 99% 
Sample #5 
(pool) 
2500 75% 66% Reject 625 57% 
Assay #3 
Animal #6 2500 89% 86% Accept 625 82% 
Animal #7 2500 83% 82% Accept 625 80% 
Animal #8 
156.25 82% 
80% Accept 39.08 82% 
9.75 77% 
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An analysis of linearity is performed to determine whether serum matrix effects interfere 
with measured results and to confirm the working range (range of the standard curve) of 
the assay.  Like recovery, linearity was also measured as a percent of observed sample 
concentration relative to the expected concentration in a sample diluted a known amount.  
The eight individual animal pools used in recovery studies were also used in linearity 
studies.  Each of the eight pools that had been spiked with the highest kit standard were 
then diluted to 50% and 20% with kit-provided assay buffer and each was measured in 
triplicate (for example, “Sample 1 with standard 7” from Table 1 was diluted to 50% and 
20% with assay buffer).  The linearity of three of these eight samples was also tested at a 
50% dilution from neat samples (i.e. a dilution was made from a serum aliquot that had 
not been previously spiked with the highest kit standard).  Each sample tested for 
linearity studies was tested in triplicate.  See Table 3 for a summary of the linearity 
studies setup and an example of calculations for a single cytokine (IL-15).  For the 
multiplexed method the acceptance criteria for linearity is 75 – 125% of expected values, 
based on common acceptance values used in the field [56], [57], [64].  
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Table 3: Summary of linearity set-up and an example of linearity calculations for a single 
cytokine (IL-15; 7 of 8 samples were within acceptable ranges, 75% - 125 %, in this case). 
IL-15 
  Dilution Linearity  Average per Animal Result 
Assay 
#1 
Animal 
#1 
Spiked with standard 7 
then diluted to 50% 142% 167.7 Reject Spiked with standard 7 
then diluted to 20% 194% 
Animal 
#2 
Spiked with standard 7 
then diluted to 50% 106% 115% Accept Spiked with standard 7 
then diluted to 20% 123% 
Assay 
#2 
Animal 
#3 
Neat, diluted to 50% 91% 
117% Accept 
Spiked with standard 7 
then diluted to 50% 121% 
Spiked with standard 7 
then diluted to 20% 141% 
Animal 
#4 
Neat, diluted to 50% 74% 
83% Accept 
Spiked with standard 7 
then diluted to 50% 88% 
Spiked with standard 7 
then diluted to 20% 88% 
Sample 
#5 (pool) 
Neat, diluted to 50% undetectable 
107% Accept 
Spiked with standard 7 
then diluted to 50% 103% 
Spiked with standard 7 
then diluted to 20% 111% 
Assay 
#3 
Animal 
#6 
Spiked with standard 7 
then diluted to 50% 116% 123% Accept Spiked with standard 7 
then diluted to 20% 131% 
Animal 
#7 
Spiked with standard 7 
then diluted to 50% 108% 116% Accept Spiked with standard 7 
then diluted to 20% 124% 
Animal 
#8 
Spiked with standard 7 
then diluted to 50% 106% 110% Accept Spiked with standard 7 
then diluted to 20% 114% 
 
Specificity data as reported by Millipore in the assay kit insert were assumed to be 
accurate.  Studies to confirm specificity of the antibodies for the 23 cytokines would 
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require complex protocols using multiple analytes that may not be traceable to known 
standards.  Therefore, specificity was not evaluated in this study. 
 
A comparison of the validation protocol used in this study with the recommended FDA 
guidelines is summarized in Table 4.  The layout of each validation plate is presented in 
Appendix B, Figure 7.  
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Table 4: Comparison of cytokine multiplex validation protocol and FDA Industry Guidelines for 
method validation. 
Parameter Definition and recommendations from 
the FDA Industry Guidance  
How it was performed in this study 
Sensitivity “The lowest analyte concentration that can 
be measured with acceptable accuracy and 
precision.” (No specific recommendations 
are made on how to evaluate this.) 
To test precision at low concentrations: 
the lowest standard was diluted to 50% 
with assay buffer and tested in two 
wells in one assay then the lowest 
standard was diluted to 25% with assay 
buffer and tested in 6 wells in another 
assay. In addition, the observed lowest 
standard concentration was compared 
to the expected concentrations. 
Precision “The closeness of individual measures of 
an analyte when the procedure is applied 
repeatedly to multiple aliquots of a single 
homogeneous volume of biological 
matrix.” The recommendation is to perform 
at least five determinations per 
concentration and a minimum of three 
concentrations in the expected range of 
sample concentrations. Incurred sample 
reanalysis (using actual samples, not QCs) 
should be performed as part of inter-assay 
precisions. No specific instructions are 
provided on how many replicates are 
needed to evaluate inter-assay precision. 
Two NHP serum pools were 
constructed (one at high 
concentrations, one at low 
concentrations) and each was tested in 
12 wells on a single plate. For inter-
assay evaluation, 2 kit provided QC 
and 2 pools of NHP serum spiked with 
kit QC were run in triplicate on 4 
separate plates. The NHP serum spiked 
with QC is meant to satisfy the 
incurred sample reanalysis as it 
incorporates actual biological matrix 
but was spiked with QC to gives 
concentrations within the working 
range of the assay.  
Accuracy  “The degree of closeness of the determined 
value to the nominal or known true value 
under prescribed conditions.” Perform at 
least five determinations per concentration 
and a minimum of three concentrations in 
the expected range of sample 
concentrations using known true samples. 
Alternatively, a confirmatory method (like 
LC-MS) can be used to verify the samples 
evaluated. 
Although the kit standards were 
considered “known true,” traditional 
accuracy was not performed. Rather 
recovery studies were done. No other 
confirmatory methods were performed. 
Recovery “The measured concentration relative to the 
known amount added to the matrix.” 
Generally only used for assays which 
require sample extraction. Specific number 
of replicates is not provided. 
Although this study does not involve 
sample extraction, recovery was 
performed in lieu of traditional 
accuracy. Since the kit standards were 
considered our “known true” sample, 
they were spiked into endogenous NHP 
serum to mimic biological matrix 
conditions. The two pools described 
for precision as well the serum from 
six other individual NHPs were spiked 
with two known concentrations of kit 
standard and each was measured in 
triplicate. 
Selectivity/ “The ability of the bioanalytical method to Specificity for structurally similar 
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Specificity measure and differentiate the analytes in 
the presence of components that may be 
expected to be present.” To evaluate 
interference from the structurally similar 
substances, these substances should be 
obtained and spiked in at known amounts; 
when possible, this should be confirmed 
with a validated reference method (like 
LC-MS). Interference from matrix effects 
should be evaluated three ways: 1. by 
linearity (a dilution series from a sample is 
compared to a dilution series of standards) 
2. By comparing the standard curve in 
buffer to the standard curve in biological 
fluids. 3. By determining the non-specific 
binding (NSB) of the assay.   
analytes was performed by Millipore 
and not confirmed in our study due to 
the interaction complexity of 23 
different analytes and the lack of 
traceable standards for all 23 analytes 
from cynomolgus macaques. Linearity 
was performed by diluting each of the 
8 samples used in recovery studies to 
50% and 20% with kit-provided assay 
buffer. The linearity of each of these 8 
samples was also tested neat (diluted to 
50% prior to any spiking with kit 
standard).  Each sample was assayed in 
triplicate. The standard curve was not 
tested in buffer alone, kit-provided 
NHP matrix was always added to 
normalize the assay. The NSB of the 
assay was determined by testing buffer 
alone (in triplicate) in each assay.  
Reproducibility “The precision between two laboratories” 
and “the precision of the method under the 
same operating conditions over a short 
period of time.”  It can be evaluated by 
comparing validation results between two 
or more laboratories performing the same 
protocol, or by a single lab repeatedly 
measuring the same QC or study sample. 
The validation results from Millipore 
were compared to our own. However, 
Millipore validated using cytokines 
from phytohaemagglutinin (PHA) or 
LPS stimulated peripheral blood 
mononuclear cells (PBMCs) from 2 
cynomolgus macaques, except for IL-
10, which was tested as LPS 
challenged serum; therefore validations 
are not directly comparable. No other 
lab validation data were found to 
compare to. Precision studies also 
provided reproducibility data. 
Stability/ 
Robustness 
“The chemical stability of an analyte in a 
given matrix under specific conditions for 
given time intervals.” Can be studied by 
assessing freeze/thaw cycles, bench-top 
handling conditions, long-term storage, 
stock solution in different states or 
different buffers, and processed sample 
stability (time to analysis), if applicable. 
Long-term storage will be evaluated in 
future studies. The NHP serum pool 
used for inter-assay QC was aliquoted 
and will remain stored at -20oC for 
future analysis and comparison. 
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 Measurement of Cytokine Concentrations Using Luminex Multiplex Technology 
A Luminex100® system was used to perform the multiplexed assays.  This system uses 
6.5µM beads, which have a superparamagnetic center with a polystyrene coating.  The 
plastic coating has a distinct spectral signature and the surface is coated with antibodies 
against distinct analytes [65].  The bead’s spectral signature is achieved using a specific 
ratio of two dyes, red and infrared, containing fluorochromes, which fill the internal 
portion of each bead.  As sample is mixed in plate wells with beads, the analyte of 
interest is captured by antibodies on the bead surface.  A secondary antibody is added and 
finally a reporter (streptavidin phycoerythrin), that produces orange fluorescence, is 
added.  As these beads flow past a red laser the internal dyes are excited and the bead is 
categorized based on the analyte it captures.  The bead continues to flow past a second, 
green, laser which excites the reporter and the amount of fluorescence is measured [66].  
The level of fluorescence correlates to the analyte concentration in the test sample.  
Luminex xPONENT Software version 3.1 was used for Luminex operation.   
 
Due to a manufacturer change in kit format (transition from polystyrene to magnetic 
beads) all measurements of cytokines in serum from NHP associated with Aim 2 were 
generated using a kit that differed by bead-type (and therefore separation technique) 
when compared to the measurements generated for the validation studies.  The NHP 
cytokine data were generated using the polystyrene-bead based kit (catalog number 
MPXPRCYTO-40K-PX23), which was discontinued.  An additional difference 
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associated with the method transition is a change in the ability to measure IL-10.  
Millipore reported that IL-10 was not detectable in lipopolysaccharide (LPS)-stimulated 
peripheral blood mononuclear (PBMC) cells from cynomolgus macaques in the 
polystyrene-bead based kit.  When the IL-10 antibody pair was changed upon transition 
to the magnetic bead format, IL-10 was then considered “strongly reacting,” when tested 
in cynomolgus macaque serum using this assay kit.  The manufacturer determined 
“reactivity” (specificity) for IL-10 using LPS-challenged serum from two cynomolgus 
macaques.  Reactivity for the other 22 cytokines was determined by testing the secreted 
products of LPS- or phytohemagglutinin-challenged PBMCs from two cynomolgus 
macaques (e.g. LPS-stimulated PBMCs from cynomolgus macaques generated IL-6, 
which then strongly reacted with the antibodies used in this kit).  A Technical 
Applications Scientist at Millipore indicated (personal communication) that no other 
antibody pairs were changed in the transition to magnetic bead technology [67].  
However, the standard curve range did change due to adjustments incorporated in the 
transition. Prior to the integration of the magnetic bead technology, all 23 analytes had 
the same standard curve range of 0.64 – 10,000 pg/mL. After the transition to the 
magnetic kit, the standard curve range for IL-4 was 4.9 – 20,000 pg/mL, for IL-10 and 
IL-18 was 12.2 – 50,000 pg/mL and for the other 20 analytes it was 2.4 – 10,000 pg/mL.  
As a result of these changes, IL-10 data are not available for the NHPs (as they were all 
tested using the polystyrene-bead based kit).  However, IL-10 validation data is presented 
(as all validation work was performed using the magnetic-bead based kit).   
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Serum samples from NHPs that were determined to contain undetectable concentrations 
of specific cytokines are recorded as containing <0.64 pg/mL as this was the lowest 
standard for the polystyrene-bead kits used for analyses.  Undetectable concentration 
levels determined as part of the validation of the magnetic bead kit are reported in light of 
the individual cytokine sensitivity level determined.  
 
Animals  
All animal procedures were approved by the University of Minnesota Institutional 
Animal Care and Use Committee, were conducted in compliance with the Animal 
Welfare Act, and adhere to principles stated in the Guide for Care and Use of Laboratory 
Animals.  Blood samples were collected from 36 healthy cynomolgus macaques (Macaca 
fascicularis) from a subcutaneous vascular access port [68] to allow for cooperative 
central venous access in the homecage.  Semi-annual veterinary physical examinations 
were performed and included weight, body condition scoring, heart rate, temperature, 
palpation of lymph nodes and abdomen and evaluation of the oral cavity, dermis, ears and 
nose.  Complete blood count and a chemistry panel were also performed.  Animals were 
enrolled in a separate islet transplantation study so the exclusion criteria were pertinent to 
that study and included body weight under 1.8 kg, severe persistent diarrhea or vomiting, 
active systemic infection, lymphopenia, neutropenia, thrombocytopenia, elevated 
hemoglobin or liver enzymes or plasmodium infection.  Blood (0.6 mL) was collected in 
Becton Dickinson serum separator microtainer tubes.  Tubes were kept cool and allowed 
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to clot for 30 minutes then centrifuged at 3,500 RPM for 20 minutes.  Samples were 
aliquoted into plastic microfuge tubes and frozen at ≤ -20oC. 
 
Of the 36 NHPs, two were female and 34 were male, all aged between 3.4 and 6.4 years 
(median 5.3 years), and weighed between 3.6 and 7.9 kg (median 5.1 kg).  All animals 
were purpose-bred and purchased from institutionally approved commercial vendors.  
They were housed in pairs or small groups of the same sex.  They had free access to 
water and were fed High-Protein Monkey Chow biscuits (Purina Mills, St Louis, MO, 
USA) based on body weight.  Their diet was enriched with fresh fruits, vegetables, 
grains, beans, nuts, and a multivitamin preparation.  The animals participated in an 
environmental enrichment program that included social play, opportunities for foraging, 
puzzle solving, music, and regularly scheduled access to exercise and swimming areas.  
 
Data Analysis 
After Luminex data acquisition, fluorescence data were analyzed with Millipore 
MILLIPLEX Analyst version 3.4.  The Millipore MILLIPLEX Analyst settings were 
selected according to manufacturer recommendations and were described as: standard 
curve fit model using a five parameter log fit with threshold slope: 0.10; threshold R2: 
0.50; threshold curve fitting: 2.00; threshold replicate data: 2.00; reporting range low 
bead count: 35 and high CV: 20.00.  Aside from the curve fit model, these settings simply 
alert the user to potentially poor data from the standard curve (poor slope, poor 
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coefficient of determination (R2), for example) or within the sample data (replicates with 
low bead counts or high CV, for example), but do not affect the analysis. 
 
The statistical analysis of the data for validation purposes was performed with the 
calculated concentrations of each sample rather than the MFI (mean fluorescence 
intensity) source data.  Validation analysis with MFI numbers may show a falsely better 
assay performance.  Calculations based on concentration values will show higher 
variation than analysis of MFI numbers as the differences in standard curves of each 
analyte must be considered.  However, analysis using concentration gives a more 
accurate representation of assay performance since actual results are reported as a 
concentration (pg/mL) rather than as an MFI number. 
 
The Tukey method (any value 1.5 times outside the inner-quartile range) was used to 
identify potential outliers.  Although outliers were detected in the cytokine concentration 
distributions, they were not excluded.  The data are presented as the full distribution of 
results because without specific criteria or justification for exclusion, all data may 
represent true values within a healthy animal.  The cytokine data collected from the 36 
monkeys were not used to generate a reference interval (RI) for the specific cytokines 
because best practice recommendations for the establishment of a de novo RI suggest that 
at least 120 reference individuals that have met specific inclusion criteria and 
categorization (age, sex, etc.) be used to generate a population-based RI [69].  The 
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objective of Aim 2 was simply to determine if the assay is suitable for the detection of 
baseline cytokine concentrations in serum from healthy cynomolgus macaques.  
 
Cytokine concentrations were measured in 36 healthy cynomolgus macaques, sometimes 
multiple samples per animal, for a total of 54 samples tested.  An average of each 
cytokine per animal was determined when more than one sample per animal was tested.  
If censored data (undetectable concentrations, listed as <0.64 pg/mL) were included in 
mean calculations, the data point was changed to half the limit of detection (i.e. <0.64 
was changed to 0.32).  If the resulting mean was below 0.64 pg/mL the mean was 
reported as “<0.64.”  Using half the limit of detection is a simple method used in place of 
more complex statistical methods for analyzing censored data [70] and is suggested as an 
acceptable method in this case as the differences of calculated averages that could have 
resulted from using 0, 0.32 or 0.64 pg/mL in analysis are miniscule.  
 
NHP cytokine distribution data will be presented as box-and-whisker plots.  The top of 
the box represents the top 75th percentile, the middle line is the median, the bottom of the 
box represents the bottom 25th percentile and the whiskers extend to the minimum and 
maximum (excluding outliers); outliers are shown beyond the reach of the maximum 
whisker. 
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 Results 
Aim 1: Method Validation Data  
Representative standard curves from validation data that were determined to be 
acceptable (IL-2), marginal (IL-10) or rejected (IL-17A) are shown in Figure 1.  The 
recovery (percent of expected to observed concentration) for each point on each standard 
curve in each assay was determined.  Occasionally there were standard curve points that 
fell outside of the acceptable 75-125% range (13 of 644 total standard curve points, 2%, 
over four assays) but trends were not identified (there were never more than three points 
of any curve outside of the expected range and trends of standard curve variability across 
multiple assays were not present.)  All standard curves obtained in this study were 
acceptable and did not contribute to the rejection of validation acceptance criteria for any 
cytokine.  Representative standard curves are shown in Figure 1 to illustrate the degree of 
uniformity between standard curves for cytokines from each validation outcome category 
(accepted, marginal, rejected).  
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Figure 1: Representative standard curves from an accepted (IL-2), marginal (IL-10), and rejected 
(IL-17A) cytokines.  Mean fluorescence intensity (MFI) is shown on the y-axis while 
concentration (pg/mL) is shown on the x-axis. 
 
 
Sensitivity 
The results of sensitivity analyses are shown in Table 5.  To briefly review terms: the 
LLOD is the lowest concentration that can be detected; the LLOQ is the lowest 
concentration that can be tested accurately (± 25% of the nominal value) and precisely 
(CV < 25%).  Both the LLOD and LLOQ was determined for each cytokine, though only 
the LLOD was used to determine if validation acceptance criteria were met (LLOD ≤ the 
lowest standard).  The lowest standard was diluted to 50% and 25% to determine first the 
LLOD (if a concentration could be detected) and second the LLOQ (if the observed value 
was both precise and accurate).  If the LLOD did not match the LLOQ, the lowest 
standard of each cytokine in each assay was reviewed determine precision and recovery 
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values, and if conditions were met, the lowest standard was set as the LLOQ.  With the 
exception of VEGF, the lowest standard for each cytokine consistently showed 
acceptable recovery and precision. In two of the four validation assays performed, the 
standard curve for VEGF showed acceptable results at all eight points (from 0 – 10,000 
pg/mL).  In one of the other two assays the VEGF standard curve did not show 
acceptable recovery values (as a percentage of observed concentration/expected 
concentration) until standard point 5 (156.3 pg/mL) and in the other curve until standard 
point 6 (625 pg/mL).  Since the ability to measure the lowest VEGF standard (2.4 pg/mL) 
is inconsistent, the LLOQ was set at the vendor’s reported sensitivity level of 13.6 
pg/mL.  Although the LLOQ for VEGF was not below the lowest standard, the LLOD for 
VEGF was below the lowest standard.  Therefore, the results of the sensitivity studies 
show this method is sensitive at or below (i.e. more sensitive) the lowest standard for all 
23 cytokines and this method meets the pre-established acceptance criteria for sensitivity.   
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Table 5: Results of sensitivity studies. The lower limit of quantification (LLOQ), lower limit of 
detection (LLOD), lowest standard and Millipore’s reported sensitivity for each analyte are 
shown.  In order to meet assay acceptance criteria, it is expected that the LLOD will be at, or 
below, the lowest standard for that analyte.    
Analyte 
Lowest 
Standard 
(pg/mL) 
LLOD 
(pg/mL) 
LLOQ 
(pg/mL) 
Vendor Reported 
Sensitivity 
(pg/mL) 
Outcome 
GM-CSF 2.4 0.6 2.4 1.8 Pass 
TGFα 2.4 1.2 1.2 1.1 Pass 
G-CSF 2.4 0.6 2.4 2.1 Pass 
IFNγ 2.4 0.6 2.4 1.6 Pass 
IL-2 2.4 0.6 2.4 2.1 Pass 
IL-10 12.2 3.05 12.2 6.4 Pass 
IL-15 2.4 2.4 2.4 0.5 Pass 
sCD40L 2.4 2.4 2.4 2.1 Pass 
IL-17A 2.4 0.6 2.4 1.3 Pass 
IL-1ra 2.4 2.4 2.4 2.4 Pass 
IL-13 2.4 0.6 2.4 5.8 Pass 
IL-1β 2.4 1.2 1.2 1.2 Pass 
IL-4 4.9 4.9 4.9 3.1 Pass 
IL-5 2.4 1.2 1.2 1.5 Pass 
IL-6 2.4 2.4 2.4 1.6 Pass 
IL-8 2.4 1.2 2.4 1.1 Pass 
MIP-1α 2.4 0.6 2.4 4.9 Pass 
MCP-1 2.4 2.4 2.4 3.1 Pass 
TNFα 2.4 0.6 2.4 1.6 Pass 
MIP-1β 2.4 0.6 0.6 1.6 Pass 
IL-12/23(p40) 2.4 2.4 2.4 1.5 Pass 
VEGF 2.4 2.4 13.6 13.6 Pass 
IL-18 12.2 6.1 12.2 6.1 Pass 
 
 
Precision 
Intra-assay precision was determined by performing 12 replicate measurements at two 
targeted concentration levels (low and high with relation to the standard curve) for a total 
of 24 observations within a single assay.  The averages of these 24 observations are 
reported as the overall intra-assay precision.  All cytokines met acceptance criteria of CV 
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< 20% for intra-assay (within plate) precision.  Inter-assay (between plate) CVs were 
generally higher than within-plate CV, as expected, since assays performed on different 
days introduce an additional variable.  Inter-assay CV was acceptable (<25%) for 22 of 
23 cytokines; TNFα showed an unacceptable inter-assay CV of 45.3%.  Inter-assay CV 
was calculated from the average of 4 different control samples (two commercial controls 
and 2 in-house NHP controls), each tested in triplicate in four assays performed on four 
separate days over six months.  The vendor reported intra-assay precision is <5% and the 
inter-assay precision is <15% for all analytes.  The current study agreed with the 
manufacturer reported CV of <5% in 18 of 23 (78%) analytes for intra-assay precision 
and in 20 of 23 (87%) analytes for inter-assay precision.  The results of the precision 
studies are presented in Figure 2; the calculated CV for each cytokine is presented in 
Appendix C, Table 13. 
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Figure 2: Precision data. For intra-assay precision n=24 in one assay. For inter-assay precision 
n=4 (4 assays in which each control was tested in triplicate). 
 
 
Recovery 
Recovery was analyzed in seven individual animal samples and one pool made from the 
serum of two healthy cynomolgus macaques.  Of these eight samples (representing nine 
animals) recovery performance varied considerably even when testing for the same 
analyte.  For example, in one assay, TGFα showed an average recovery of 114% in 
animal #1 while animal #2 resulted in an average TGFα recovery of 70%.  In another 
assay, animal #3, #4 and #5 showed average TGFα recovery of 93%, 204% and 88% 
respectively.  This animal-to-animal cytokine recovery variability was also seen in other 
analytes (IFNγ, IL-10, MIP-1α, TNFα).  Some cytokines were consistently recovered 
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across individual animals and assays.  For example, IL-5, IL-8 and MCP-1 all had 
acceptable recovery levels across all determinations.  However, GM-CSF was recovered 
at percentages from 200% - 300% across all animals and across all assays suggesting that 
these results are overestimated due to some form of interference or artifact.  IL-17A, IL-
4, MIP-1β and IL-18 showed consistently low recoveries across animals and assays 
which could reflect an underestimate of true values.  
 
 To meet assay acceptance criteria, recovery is expected to be 75% to 125% of expected 
values. The manufacturer reported recovery (reported as “accuracy”) results ranging from 
87-101% for 22 out of 23 cytokines, the 23rd cytokine, VEGF, was reported to have an 
accuracy of 70%.  The results reported here agree with manufacturer reported recovery 
for one cytokine and disagree (data reported here do not meet recovery expectations) with 
manufacturer reported recovery for 18 of 23 cytokines.  Recovery for 4 cytokines in the 
current study was better (closer to 100% of the expected values) than that reported by the 
manufacturer.  Results of recovery studies are presented in Figure 3 and calculated 
recovery values, along with manufacturer reported accuracy values are presented in 
Appendix C, Table 14. 
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Figure 3: Recovery results. Seven individual animal samples and one NHP serum pool were 
spiked with known amounts of standard at various levels to yield 17 separate spiked samples, 
each measured in duplicate, over 3 assays.  Each recovery point plotted here is the average of 
duplicates from one of the 17 spiked samples.  The shaded band from 75% - 125% indicates the 
acceptable range.  
 
 
 
 
Linearity 
Linearity is studied by diluting a sample of known concentration to specific dilution 
levels and comparing the observed concentration to the expected concentration after 
analysis.  Acceptance criteria require that observed concentrations are determined to be 
75-125% of expected concentrations.  Endogenous cytokines in healthy animals are 
generally very low or undetectable for most of the 23 cytokines tested here [5], [71], 
making dilution studies unreliable in the samples from these healthy animals.  Therefore, 
some NHP samples were spiked with the highest standard in order to create a dilution 
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series.  When possible, the average linearity of neat (un-spiked) samples is shown in 
addition to average linearity from the sample spiked with standard.  Since endogenous 
cytokine concentration was expected to be low, a dilution series was not constructed from 
the un-spiked samples; rather a single 50% dilution of these samples was performed.  
Spiked samples were diluted to 50% and 20% in seven individual animals and one serum 
pool, each of the resulting dilutions were analyzed in duplicate across three assays, over 
three weeks.  All three samples that were tested neat had undetectable levels of GM-CSF 
and IL-1β, therefore no linearity data could be gathered for those analytes until additional 
GM-CSF or IL-1β was spiked in.  The results of the linearity studies are presented in 
Figure 4 and calculated linearity results are presented in Appendix C, Table 15.  The 
manufacturer did not generate linearity data from this method.  
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Figure 4: Linearity results from neat samples and samples spiked with the highest assay standard. 
Arrows indicate cytokines that were undetectable when tested neat. The shaded horizontal band 
indicates the acceptable linearity range (75% - 125%). Arrows indicate undetectable levels where 
dilutions could not be performed. 
 
 
 
Acceptance Criteria 
Each of the 23 cytokines were categorized as acceptable, marginal or rejected based upon 
whether the measurement characteristics met validation acceptance criteria for sensitivity, 
recovery, precision and linearity.  All of the cytokines met the acceptance criteria for 
sensitivity and intra-assay precision, and all but one cytokine, TNFα, met the acceptance 
criteria for inter-assay precision.  Categorization results for recovery and linearity are 
summarized in Table 6.  The tests for recovery and linearity were performed in seven 
individual animals (because individual animal variation is expected) and one pool made 
57 
 
 
from the serum of two cynomolgus macaques.  More than half of these eight individual 
samples tested for recovery had to meet acceptance criteria (75-125%) to be classified as 
“accepted” for categorization purposes. Additionally, either the linearity of all samples 
diluted neat (without addition of kit standard) had to fall in the acceptable range, or the 
linearity of more than half of all samples (regardless of dilution neat or after spiking) had 
to fall in the acceptable range to be classified as “accepted” for categorization purposes.  
If both conditions were met for recovery and linearity then the cytokine was categorized 
as “accepted,” if neither condition was met then it was classified as “rejected” and if it 
met only one of the two conditions it was classified as “marginal”.   
 
TNFα failed to meet acceptance criteria for inter-assay precision, recovery and linearity. 
Therefore this method is not suitable for the measurement of TNFα and it is categorized 
as ‘rejected’.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
 
Table 6: Validation categorization and outcomes for the 23 cytokines included in the NHP 
cytokine panel.  
Cytokine Acceptable Recovery* 
Acceptable  
Linearity** 
Validation 
Outcome 
GM-CSF no no Reject 
TGFα yes yes Accept 
G-CSF yes no Marginal 
IFNγ yes yes Accept 
IL-2 yes yes Accept 
IL-10 no yes Marginal 
IL-15 yes yes Accept 
sCD40L yes no Marginal 
IL-17A no no Reject 
IL-1ra no no Reject 
IL-13 yes yes Accept 
IL-1β no no Reject 
IL-4 no yes Marginal 
IL-5 yes yes Accept 
IL-6 yes yes Accept 
IL-8 yes yes Accept 
MIP-1α no yes Marginal 
MCP-1 yes yes Accept 
TNFα no no Reject 
MIP-1β no no Reject 
IL-12/23(p40) yes yes Accept 
VEGF yes yes Accept 
IL-18 no no Reject 
*>50% of the data from the eight samples demonstrated average acceptable recovery (75-125%) 
**>50% of the data from the eight animals tested demonstrated acceptable average linearity 
AND/OR overall acceptable linearity (75-125%) of endogenous (neat) samples 
 
This research demonstrates that when this multiplex method is used, 11 out of the 23 
cytokines (48%) can be reliably measured based upon the method being demonstrated to 
meet validation criteria. Five cytokines (22%) were determined to be of marginal 
reliability because all validation criteria were not consistently met.  Method validity for 7 
of the 23 cytokines (30%) could not be assured and so the use of this method for those 
analytes was rejected.  These results are summarized in Table 7.   
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Table 7: Validation outcome for the 23 cytokines in the multiplex assay kit.  
Accept Marginal Reject 
TGFα G-CSF GM-CSF 
IFNγ IL-10 IL-17A 
IL-2 sCD40L IL-1ra 
IL-15 IL-4 IL-1β 
IL-13 MIP-1α TNFα 
IL-5   MIP-1β 
IL-6  IL-18 
IL-8   
MCP-1   
IL-12/23(p40)   
VEGF   
 
The 11 cytokines categorized as accepted have met acceptance criteria for sensitivity, 
precision, recovery and linearity.  All five of the marginal cytokines (G-CSF, IL-10, 
sCD40L, IL-4 and MIP-1α) had acceptable intra- and inter-assay precision but varied in 
their recovery and linearity performance.  G-CSF showed acceptable recovery (75-125%) 
in four of the seven animals tested (samples tested for the eighth animal had low bead 
counts and no results were available), while two of the eight animals showed recovery 
ranges near 70%.  Linearity was acceptable for G-CSF in two of the three samples tested 
neat, but not for any of the other samples tested.  Next, IL-10 showed acceptable recovery 
in two of eight animals, while the remaining six animals resulted in recoveries ranging 
from 23% - 70%.  Linearity of IL-10 was very similar to recovery data in that only three 
of eight animals showed acceptable linearity results.  Recovery for sCD40L was 
generally acceptable with four of six animals showing acceptable results (results were not 
obtained for one animal due to low bead count and for another due to very high results 
that were above the readable range).  Linearity was, however, poor for sCD40L as only 
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one of seven animals showed acceptable results.  In contrast to sCD40L, IL-4 showed 
poor recovery but acceptable linearity: none of the eight animals tested for recovery 
showed acceptable results, but half of those same animals showed acceptable linearity 
results.  Finally, recovery for MIP-1α was acceptable in two of eight animals while 
recovery for two other animals was just outside the acceptable range.  Linearity of MIP-
1α was acceptable in four of eight animals.  This study demonstrates that the multiplex 
method is not fit for purpose for measuring these 7 cytokines. Concentrations of these 7 
cytokines measured in the NHP as part of thesis Aim 2 are provided for completeness 
(but not interpretation) in Appendix D.  
 
Aim 2: Measurement of Cytokines in Non-Human Primate Serum 
Non-human primate data for the 15 cytokines that were classified as accepted or marginal 
for method acceptability are presented in Table 8 (although IL-10 validation data were 
considered marginal, it is not included here as NHP data are not available for this 
cytokine due to the assay format transition described previously).  The median, mean, 
standard deviation and percentage of samples within the working range (standard curve 
range) of the assay is shown for each cytokine to illustrate concentration distribution.   
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Table 8: Cytokine concentration distribution for 36 individual NHP (averages were calculated for 
animals with multiple samples). 
Analyte Range (pg/mL) 
Median 
(pg/mL) 
Mean 
(pg/mL)  
Standard 
deviation 
(pg/mL) 
% of samples 
within working 
range of assay 
G-CSF <0.64 - 18.4 3.7 4.6 4.5 68% 
IFNγ <0.64 - 98 2.0 9.4 19.5 78% 
IL-4 <0.64 - 2.8 <0.64 <0.64 N/A 11% 
IL-2 1.3 - 78 8.4 12.5 13.5 100% 
IL-5 <0.64 - 15 <0.64 1.2 2.7 28% 
IL-6 <0.64 - 46 <0.64 2.6 4.3 44% 
IL-8 271 - >10,000 2,033 2,962 2,923 97% 
IL-12/23 (p40) 24 - 584 96.3 130 116 100% 
IL-13 <0.64 - 13 2.2 3.0 2.8 83% 
IL-15 <0.64 - 18.4 3.4 4.6 4.0 92% 
MCP-1 102 - 632 344.2 360 129 100% 
MIP-1α <0.64 - 256 7.9 17.6 42.4 86% 
sCD40L 188 -  >10,000 4,956 5,511 3,086 89% 
TGFα 2.4 - 47 8.4 11.5 9.6 100% 
VEGF <0.64 - 1,798 10.3 93 305 81% 
 
For comparison purposes, Table 9 provides human cytokine concentration ranges 
obtained using the manufacturer’s human multiplex kit counterpart to the NHP kit.  The 
human data presented in Table 9 were provided by the manufacturer with the disclaimer 
that because of sample size and randomization limitations, data represent a guideline and 
not an established reference range [72].  Figure 5 displays the percent of samples tested 
that are within the detectable ranges of the assays.  Comparisons between NHP and 
human are of interest because there are similarities between the human and non-human 
primate, and the observed cytokine ranges may be similar.  In addition, when necessary, 
NHPs are used in research trials to evaluate safety and efficacy prior to translation for use 
in the human.  
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Table 9: Cytokine concentration range determined in human and NHP sera.  The concentration 
range (and percent of samples within the working range of the assay) are presented.   
Cytokine Concentration Range, Human 
(pg/mL; n=20)* 
Concentration Range, NHP 
(pg/mL; n=36) 
G-CSF <3.2 – 756 (50% detectable) <0.64-18.4 (68% detectable) 
IFNγ <3.2 – 22.2 (60% detectable) <0.64-98 (78% detectable) 
IL-4 <3.2 – 10.7 (75% detectable) <0.64-2.8 (11% detectable) 
IL-2 <3.2 – 102 (55% detectable) 1.3-78 
IL-5 <3.2 – 403 (70% detectable) <0.64-15 (28% detectable) 
IL-6 <3.2 – 10 (95% detectable) <0.64-22 (44% detectable) 
IL-8 <3.2 – 156 (55% detectable) 271-  >10000 (97% detectable) 
IL-12/23(p40) <3.2 – 27.9 (30% detectable) 24-584  
IL-13 <3.2 – 362 (55% detectable) <0.64-13 (83% detectable) 
IL-15 <3.2 – 14.9 (70% detectable) <0.64-18.4 (92% detectable) 
MCP-1 <3.2 – 81.8 (60% detectable) 102-632  
MIP-1α    63.5 – 439  <0.64-256 (86% detectable) 
sCD40L <3.2 – 6.4 (5% detectable) 188- >10000 (89% detectable) 
TGFα <3.2 – 118 (85% detectable) 2.4-47  
VEGF <3.2 – 118 (75% detectable) <0.64-1798 (81% detectable) 
*All human cytokine concentration data provided by Millipore as obtained from their Milliplex 
MAP Human Cytokine/Chemokine 42-plex panel (catalog number MPXHCYTO-60K) [73]. 
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Figure 5: The percent of NHP and human samples that are within detectable ranges of the 
respective assays. 
 
 
 
The box and whisker distribution plots for cytokines measured in each animal (only 
accepted and marginal data displayed) are provided in Figure 6.  Points representing 
samples outside the limit of detection are differentiated by shape (open circles).  Outliers 
are shown beyond the reach of the maximum whisker and were calculated as being ≥ 1.5 
times the inner-quartile range (IQR) above the 75th percentile.   
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Figure 6: Distribution of cytokine concentrations obtained from healthy cynomolgus 
macaques Top of the box = 75th percentile; middle line = median; bottom of the box = 
25th percentile; whiskers extend to the minimum and maximum (excluding outliers); 
outliers are shown beyond the reach of the maximum whisker. 
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 Discussion 
The aims of this thesis were 1) to determine if a multiplex method for the measurement of 
multiple cytokines in NHP serum was valid, accurate and reliable and 2) to use the 
method to determine if the assay is suitable for the detection of cytokine concentrations in 
a study population of healthy cynomolgus macaques.    
 
Aim 1: Method Validation Data 
Validation is necessary to demonstrate 1) that a method is fit for its intended purpose, and 
2) to demonstrate that the method will work as described by the manufacturer under the 
laboratory and sampling conditions required to meet research objectives.  For instance, 
method validation is especially critical when a test method manufactured for use in one 
species is applied to other species because the blood or serum matrix will differ among 
species and this difference may affect method performance.  In the current study, a 
validation of the multiplex method for cytokine analyses in the NHP was performed by 
evaluating the sensitivity, precision, recovery, and linearity of the procedure when used 
with serum from cynomolgus macaques. Acceptance criteria for method validity were 
pre-established and based on commonly used parameters for the multiplexed method 
[56], [57], [64].   
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Multiplexing technology has significant animal welfare (reduced animal handling and 
sample volume) and research (increased efficiency) advantages when compared to 
traditional methods like ELISA, due to the ability to simultaneously measure multiple 
analytes (cytokines) from one small volume (25 µL or less) sample.  While multiplex 
assays cost more than ELISA, they become cost effective when four or more analytes can 
be accurately measured in one sample as opposed to performing four individual cytokine 
ELISAs) [74].  Understandably, multiplexed assay costs increase as the number of 
analytes being measured increases; therefore, it is critical to confirm that the method is 
appropriate for each analyte.  Because cytokines exist as part of a complex and inter-
connected network, simultaneous detection of these biomarkers presents an opportunity 
to measure a panel of cytokines, rather than a single cytokine.  While these advantages 
are compelling, the procedures for validating a multiple analyte method will be more 
complex because error and variability are not likely to be constant or consistent within a 
panel grouping in spite of effort by the manufacturer to optimize the procedure for all 
analytes. 
 
In order to identify and understand the error and variability associated with a method, it is 
necessary to determine if the assay is fit-for-purpose by performing a method validation 
assessment prior to using the method to meet research or clinical objectives in the species 
of interest.  As summarized in the Introduction, previous studies provide validation data 
for multiplex methods used with human samples [41], [55–57], [74], [75], however, 
information related to method suitability for use with  NHP samples is limited.  
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Data from the current study demonstrate that the precision of the multiplex method is 
acceptable and comparable to that reported by the manufacturer for most of the 23 
cytokines in the measurement panel.  However, for 18 of the 23 cytokines, the recovery 
and linearity of the method were highly variable, generally unacceptable, and not 
favorably comparable with the spike-recovery results reported by the manufacturer.  For 
example, none of the 23 cytokines met the recovery acceptance criteria (75 to 125 %) in 
all eight (or even seven) of the animal samples tested.  Six of the eight animals had 
acceptable recovery for seven cytokines but, in contrast, there were also six cytokines 
where none, or only one, of the animals demonstrated acceptable recovery results.  
Similarly, the linearity results were also highly variable: across the 23 cytokines, 
anywhere from zero to all eight of the animals had acceptable linearity results.  Prabhakar 
et al. found similar inconsistencies using a human multiplex kit (Linco) for use with 
human serum samples; they demonstrated acceptable precision (<20% intra-assay and 
25% inter-assay), but highly variable recoveries (28% - 127%) for the six cytokines 
tested [56].  When using a human Biorad 17-plex cytokine kit, Siawaya et al showed 
recovery results with similar variability to those presented in this thesis; they observed 
recovery ranges from 20% - 325% [55].  The poor recoveries demonstrated in assays 
from different manufacturers suggest that accurate measurements can be difficult to 
obtain with the multiplexed method.  Therefore, the tradeoff of convenience and 
efficiency may not be worth the loss in data reliability for some of the analytes tested.    
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Because cytokines typically have short half-lives [31] and are potent and can exert their 
effects at picomolar concentrations [5], it is important to confirm the sensitivity of each 
method for each analyte.  In the validation study reported here, sensitivity measures met 
the acceptance criteria (at or below the concentration level of the lowest standard) for all 
23 cytokines evaluated.  
 
Some cytokines, such as IL-17A, MIP-1β and IL-18, demonstrated consistently low 
recovery results and were subsequently rejected based on this failure to meet required 
acceptance criteria.  Poor recovery may be caused by cross-reactivity, which can result 
from matrix-effects.  Matrix-effects may arise because of the protein rich environment of 
biological fluids which includes proteases, binding proteins, or other proteins structurally 
similar to the cytokine being measured.  It has been shown that alpha-2 macroglobulin, a 
common plasma protein (i.e. part of the blood matrix) can lower the measurements of IL-
2, IL-6, IL-4, IL-1β and TNFα in ELISA assays by up to 26% [77].  The role of this 
protein in the study reported here is unknown, but it is feasible that it may affect other 
cytokines in ELISA, and perhaps, in multiplex cytokine measurements as well.  
Similarly, autoantibodies to IL-6 and IL-1α have proven to inhibit their respective 
cytokines in vitro, resulting in falsely low ELISA measurements [78], [79].  Soluble 
receptors for cytokines, such as TNFα, can also be present in the blood matrix and have 
been implicated in erroneously high cytokine measurements, adding additional potential 
for interference [80].  In the pilot study for Enbrel (etanercept), a soluble TNFα receptor 
used to neutralize biological TNFα activity, patients with multiple myeloma had a 
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significantly increased plasma TNFα concentration during treatment than prior to 
treatment (median 8.0 pg/mL pre-treatment, 244 pg/mL during Enbrel treatment) [81].  
Eason et al. reported that etanercept acts as a carrier, extending the half-life of TNFα 
which may account for the higher concentration observed in treated patients [82].  This 
group also reported that although high TNFα concentrations were detected,  there was an 
undetectable level of TNFa bioactivity, which leads to the conclusion that both free and 
bound TNFα could be detected using the methods employed in that study (ELISA from 
R&D Systems).  Due to the proprietary nature of manufacturer antibody binding sites, it 
is unknown if Millipore’s NHP cytokine assay would detect both free and bound TNFα.  
If etanercept is administered to NHPs (as may be done during transplant studies) it may 
result in higher serum TNFα concentrations than in animals that did not receive 
etanercept.  Diurnal and seasonal fluctuations in certain matrix proteins (blood clotting 
factors and various hormones) have been documented in humans [82–84] indicating a 
potential source of the intra- and inter-animal variability observed in the samples tested.  
In fact, cortisol, which has a diurnal fluctuation, has been observed to inversely affect the 
inflammatory cytokines IFNγ, TNFα, IL-1 and IL-12.  Normal, lower levels of cortisol in 
humans from midnight to 5:00 am may contribute to the reported increase of 
inflammatory symptoms during these times [86].  This relationship also suggests that the 
cortisol secreted in response to acute or chronic stress may influence concentrations of 
cytokines at any given time.  
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The multiplex kit being tested in this thesis is described as being a NHP based method.  
However, many of the reagents are human based.  A human protein source is used for the 
standards and controls for 14 of the 23 cytokines, detection antibodies were raised against 
human proteins for 21 of the cytokines and the normalizing matrix is made from human 
serum.  To ensure that the assay works with NHP samples, the manufacturer determined 
reactivity for all 23 analytes in seven species of NHP (chimpanzee, baboon, rhesus, 
cynomolgus, pigtail, African green and marmoset) by collecting serum and PBMCs from 
two animals of each listed species.  Serum was challenged with LPS, and PBMCs were 
challenged with LPS or phytohemagglutinin, then the samples were testing using the 
assay kit and categorized as “+++,” (strongly reacting) “++,” “+/-” or “-,” (no detectable 
response).  Although this technique semi-objectively indicates reactivity, it does not 
describe efficiency in antibody binding of the different cytokines.  In a study that 
compared amino acid homology for 14 cytokines (ten in common with the cytokines 
studied in this thesis) between human, rhesus macaque, pigtailed macaque and sooty 
mangabey, cytokine amino acid homology ranged from 93% to 99% between humans 
and NHPs, and ranged from 97% to 100% homology between NHP species [87].  
Although minor, if these species-specific differences occur at a critical antibody binding 
site, they could contribute to the variability identified in this study. 
 
Five cytokines were determined to be ‘marginally’ acceptable for meeting method 
validation criteria.  In general, the main problem with these analytes was the lack of 
consistency among observed results within animals and between assays.  Possible 
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explanations again include the interfering effects of matrix components both within 
animals and over time (analyte stability).  Protein instability challenges the optimization 
of multiplex systems because preservatives may not equally and consistently protect all 
analytes.  
 
Some individual cytokine measurements were consistently imprecise.  For example, 
TNFα measurement achieved acceptable intra-assay precision performance, but failed 
when evaluated for inter-assay precision, with a high CV of 45%.  Of the four controls 
used to determine inter-assay precision for TNFα, three were at the low end of the 
detectable range; with average concentrations of 2.5 pg/mL, 12.9 pg/mL and 18.6 pg/mL 
(detectable range for TNFα is 2.4-10,000 pg/mL).  Therefore it is expected that precision 
will be reduced at the lower limit of the detectable range, and as recommended by the 
FDA, higher acceptable CVs are appropriate at the lower level of quantitation (LLOQ).  
However, in this case, even the fourth control for TNFα, which had an average 
concentration of 373 pg/mL, replicated poorly (39% CV) between plates. Given that the 
detectable range of this cytokine extends to 10,000 pg/mL, 373 pg/mL is a relatively low 
concentration; however the majority of the other 22 cytokines had average control 
concentrations as low as, or lower than, 373 pg/mL but still performed within acceptable 
limits.  TNFα is known to be particularly labile so it is possible that even the use of 
freshly reconstituted controls will not assure its stability and acceptable inter-assay 
precision. 
 
72 
 
 
In a study by Breen et al., in which the differences in results between labs, manufacturers 
and lot numbers of cytokine multiplexed kits were reviewed, it was shown that 
reproducibility between labs can be poor and that relative concentrations and changes in 
animals over time were of more value than the absolute concentration observed [44].  
With different manufacturers, this likely has to do with variable antibody pairs, which 
remain proprietary secrets.  In the current study, all data represent work performed using 
the same kit lot number, laboratory site and technician. Therefore, the testing 
environment should be optimal for generating consistent test results.  These complexities 
suggest that, not unexpectedly, consistency in laboratory methods is important.  
 
To summarize the first aim of this thesis, we have described the sensitivity, precision, 
recovery and linearity for each cytokine in the multiplex panel.  We have categorized the 
method validity for the measurement of each of the 23 cytokines as being approved, 
marginal (G-CSF, IL-10, cSD40L, IL-4 and MIP-1α) or rejected (GM-CSF, IL-17A, IL-
1ra, IL-1β, TNFα, MIP-1β and IL-18).  These results are critical when selecting cytokine 
analyses for research or clinical use and for the appropriate interpretation of cytokine 
results when this method is used.  For instance, for cytokines like IL-2, IL-5 and MCP-1 
(all accepted), that are both accurately and precisely measured, we have evidence that 
testing samples in duplicate will give us results representative of the true concentration.  
For analytes with poor recovery but good precision, like GM-CSF, IL-17A and MIP-1β 
(all rejected), we are unlikely to get an accurate result no matter how many times we 
repeat it.  For cytokines that have good recovery but poor precision (not identified in this 
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study) it would be desirable to test samples many times to get average results that 
approximate true concentrations.  Finally, cytokines with poor recovery and poor 
precision (not represented in this study) should not be measured with this method as they 
have been demonstrated to be unreliable (not fit for purpose) and uninterpretable.   
 
In diagnostic service and research environments, it is critical to define the inherent error 
and limitations of the methods performed in order to make recommendations for their 
appropriate use.  In the current study, results indicate that some cytokines in the 
commercial panel can be reliably measured and others cannot.  Once those limitations are 
understood, it may be possible to improve the performance by optimizing the method 
further, either within the laboratory of use or at the manufacturer level.  Manufacturers 
may be able to improve method performance based on the independent findings and 
feedback of product users.  For instance, manufacturers might respond by determining if 
native proteins have any advantage over recombinant proteins when trying to reduce 
variability of results. 
 
Measuring cytokines in bodily fluids is complicated because cytokines degrade quickly; 
cytokines in urine disappear within hours when kept at room temperature and are only 
stable for several weeks when maintained at -80oC [88].  Additional protease inhibitors 
can be added to samples (especially for very labile cytokines, like TNFα) to mitigate 
issues with protein instability.  The interference of other proteins in the sample matrix 
can often be a problem in ligand-binding assays but options exist for combating this.  A 
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2009 study by Julie Doucet et al. reported on the successful reduction of matrix 
interferences in an ELISA for monoclonal antibodies in cynomolgus monkeys.  This was 
achieved by adding a specific mixture of dimethyl sulfoxide (DMSO) and a chaotropic 
salt (a salt that dissociates and disrupts hydrogen bonding, such as NaSCN or MgCl2) to 
aid in reducing the number of non-specific (weak) interactions while leaving specific 
(strong) interactions intact [89].  Again, given that there are numerous cytokine binding 
events happening in the same well, this method may work better for some cytokines than 
for others.   
 
Data reported here and in the literature point to a difficulty in obtaining consistent and 
accurate results using the multiplex method.  Although manufacturers may report 
validation data for multiplexed assay kits, the research community cannot assume that the 
assay will work the same way in all settings and must determine these characteristics in 
their own laboratories.  
 
Aim 2: Measurement of Cytokines in Non-Human Primate Serum 
The second aim of this study was to determine if the methods tested in Aim One would 
be useful for the measurement of cytokines in healthy cynomolgus macaques.  As 
mentioned in the Introduction, many of the cytokines studied here are involved in 
inflammatory and immune response pathways and are not expected to be present at high 
concentrations in peripheral blood of healthy animals.  Under these conditions, sensitive 
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methods are required to accurately detect low concentrations.  Therefore, method 
sensitivity and additional performance measures were evaluated in Aim One.  Aim Two 
was designed to evaluate whether the multiplex method can detect baseline cytokine 
activity in healthy cynomolgus macaques.  Namely, Aim One was designed to evaluate 
the technical performance of the method and Aim Two was designed to evaluate the 
practical performance of the method for use with samples from healthy cynomolgus 
macaques.   
 
The 15 cytokines that were considered either acceptable or marginal were reviewed to 
determine if the values observed in the cohort of 36 healthy NHP were generally 
comparable to what has been reported in healthy humans using the Millipore multiplex 
method.  Available data reflecting human cytokine values are summarized in Table 9.  
The cytokine, IL-10, which was not detectable in cynomolgus macaque serum using the 
polystyrene-bead assay kit, was excluded from this review. 
 
The NHP cytokine data observed for IL-2, IL-4, IL-6, IL-15, and TGFα are similar to the 
human data reported for these cytokines (reported by Millipore using data obtained from 
their human cytokine multiplex assay; see Table 9). 
 
Low or systemically undetectable levels of G-CSF are expected in healthy NHPs, and 
low values were observed (<0.64 – 18.4 pg/mL; 68% detectable) in this study.  In 
addition, a similar percentage of samples had detectable concentration in the 20 people 
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tested by Millipore (50%) as had detectable concentration of G-CSF in the 36 NHPs 
(68%) sampled in this study.  Because G-CSF is an activator of neutrophilic activity and 
neutrophil turnover is so high (about 1.6 billion cells per kilogram per day, in humans) 
[90], some neutrohpilic stimulation is necessary for normal immune function.  However, 
neutrophil stimulation via G-CSF is not expected to be high in healthy human adults 
except during times of immunological challenge (e.g. bacterial infection) [91].  The 
highest G-CSF concentration reported by Millipore, using their human cytokine 
multiplex kit, is 756 pg/mL, which corresponds to a reported average G-CSF 
concentration found in people in the acute stage of infection (732 pg/mL) [91].  It is 
possible that one of the subjects tested by Millipore may not have been healthy.   
 
IFNγ is critical for viral immunity but is expected to be low in healthy individuals.  
Millipore reported that 60% of human samples tested for IFNγ were between 3.2 and 22.2 
pg/mL while the remaining 40% were undetectable.  In the present study, eight (22%) of 
the NHPs had undetectable IFNγ concentration while the remaining 78% had IFNγ 
concentrations from 0.76 pg/mL to 97.6 pg/mL.  The animals included in this study are 
not guaranteed to be pathogen free and some are known carriers of Campylobacter, 
Shigella, Salmonella, and/or E. coli bacteria.  In addition, temporary leukocytosis is 
commonly observed in many of these NHPs, possibly due to reactivation of latent viral 
infections (e.g. Epstein-Barr virus, cytomegalovirus).  Although all animals were 
clinically asymptomatic, this could also cause increased IFNγ concentrations.   
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IL-5 is important for promoting the growth of eosinophils which play an important role in 
helminth immunity, allergies and asthma.  Likewise, IL-13 plays an important role in 
allergic conditions due to its role in immunoglobulin isotype switching to IgE [92].  IL-5 
and IL-13 are therefore not expected to be high in healthy individuals [93].  IL-13 was 
found to range from undetectable levels up to 13 pg/mL in the NHPs but the human range 
was reported (by Millipore) to be <3.2 – 362 pg/mL.  Only 10 of the 36 NHPs (28%) had 
IL-5 concentration above the detection level and then the highest value was only 15 
pg/mL, whereas 70% of the humans tested showed detectable levels, up to 403 pg/mL.  In 
a study from 1994 comparing IL-5 levels in asthmatic patients and their healthy 
counterparts, the healthy patients all showed IL-5 levels less than 40 pg/mL, whereas 
patients with asthma had a range of IL-5 from 40 – 690 pg/mL [93].  The IL-5 levels 
observed in the NHPs seem to fit the expected ranges for healthy subjects while the IL-5 
levels reported by Millipore for humans suggest that some of the subjects may have 
allergies or asthma; the high level of IL-13 reported by Millipore in their subjects 
supports this hypothesis.   
 
Il-8 is a proinflammatory cytokine that acts as a neutrophil chemoattractant [94].  Sun et 
al. reported low levels of IL-8 in healthy adults (5 – 11 pg/mL), while their diseased 
counterparts (patients with oral lichen planus, an inflammatory disease) showed IL-8 
levels of 5 – 449 pg/mL [95].  In a study by Zimmermann et al., people with end-stage 
liver disease were shown to have serum IL-8 concentrations as high as 1500 pg/mL [96].  
The range of IL-8 reported by Millipore in human subjects was <3.2 – 156 pg/mL, again 
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suggesting the possibility that at least one subject tested was unhealthy, based on the 
literature cited here.  In contrast, Barra et al. reported that 27 healthy controls showed IL-
8 ranging from 35 - >20,000 pg/mL.  This wide range fits more closely with the range of 
IL-8 observed in the NHPs in this study (which ranged from 271 - >10,000 pg/mL).    
The validation data obtained for IL-8 showed an average recovery of 91% demonstrating 
that the assay can accurately detect this cytokine; therefore a biological explanation is 
needed.  Again, asymptomatic bacterial activation could account for the high 
concentrations of this proinflammatory cytokine but further study of this interesting result 
is needed to make conclusions. 
 
The shared p40 portion of IL-12 and IL-23 can act as its own cytokine, blocking the 
binding of IL-12 and IL-23, thereby limiting inflammation [97].  Millipore has reported 
that human IL-12/IL-23(p40) ranged from <3.2 – 28 pg/mL and only 30% of subjects had 
levels over 3.2 pg/mL.  Human blood stimulated with LPS for 24 hours has been found to 
have p40 concentrations up to 334 pg/mL, when tested using a Millipore multiplex assay 
[98].  These data suggest that low (<30 pg/mL) levels may be normal while elevated 
levels could indicate a disease state.  However, Wang et al. reported in 2013 that p40 
levels in osteosarcoma patients were 202 pg/mL while the healthy controls were observed 
to have higher average p40 levels at 269 pg/mL [99].  The average concentration of IL-
12/23(p40) in the NHPs was 130 pg/mL (median 88 pg/mL) and the three highest IL-
12/23(p40) concentrations measured were found to be outliers (at 261, 473 and 584 
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pg/mL, using the Tukey method).  Until more data can be obtained, these results 
represent the range of variation in healthy cynomolgus macaques. 
 
MCP-1 attracts monocytes to inflammation sites and was reported by Millipore to be 
undetectable in eight people while the remaining 12 people showed levels up to 82 
pg/mL.  This is considerably lower than the range observed in the NHPs tested (102-632 
pg/mL).  Reactivation of latent viral infection could account for the higher concentrations 
observed in NHPs than in humans, or perhaps this cytokine is regulated differently in 
NHPs than in humans.    
 
MIP-1α is important in attracting monocytes and B cells and contributes to local 
inflammation, in vivo.  Therefore, it is not expected that this cytokine would be elevated 
in healthy individuals.  In the NHPs tested here, the median MIP-1α level was 
determined to be 8 pg/mL and the range of results spanned from undetectable levels to 
256 pg/mL (which was statistically identified as an outlier).  Reported values in humans, 
however, are higher than these NHP values: Millipore noted a range of 64 – 439 pg/mL 
and Ding et al. showed an average value for healthy individuals as 118 pg/mL [100].  It is 
possible that the human subjects tested for MIP-1α could have been experiencing some 
inflammatory event without showing outward symptoms of disease.  Interestingly, 
depression has been associated with chronic inflammation [101] and a 2004 study 
showed that at least some depressed patients had elevated MIP-1α levels [102], which 
could account for some of the elevated levels reported in humans.  
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The soluble CD40 ligand (sCD40L) is a platelet-derived protein that is involved in 
inflammation.  While Millipore reports a human range of this cytokine from <3.2 – 6.4 
pg/mL, all of the NHPs showed elevated levels, from 188 - > 10,000 pg/mL.  Wolf et al. 
reported significantly increased plasma concentration of this cytokine in HIV infected 
patients (mean 2,300 pg/mL) than in control subjects (mean 700 pg/mL), due to 
activation of platelets (which produce sCD40L) [103].  It has also been shown that 
Epstein-Barr virus (EBV) activates platelets [104].  Therefore, if any of the NHPs were 
experiencing asymptomatic reactivation of EBV or a similar virus, it could account for 
the high sCD40L concentrations observed in this study.     
 
Vascular endothelial growth factor (VEGF) is important in regulating the formation of 
new blood vessels and is necessary for wound healing. While Millipore reported low to 
moderate levels of VEGF in humans (<3.2 – 118 pg/mL), the NHPs generated an overall 
range of <0.64 – 1,798 pg/mL, and a median value of 10 pg/mL.  All of the animals 
studied had vascular access ports (VAP) surgically implanted, possibly leading one to 
posit this as the cause of the higher VEGF concentrations in these animals.  However, 
VAP placement date did not correlate with higher VEGF concentrations; for the five 
animals with VEGF concentrations determined to be outliers (from 202-1,798 pg/mL), 
VAP placement ranged from 1 day to 14 months prior.  The cause of the wide range of 
VEGF concentrations in NHPs and the discrepancy with human VEGF concentrations 
will require further study.     
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It may be tempting to use the data generated from these 36 (34 male, 2 female) healthy 
NHPs to suggest a normal reference interval for the cytokines found to be accurately 
measured in cynomolgus macaques.  However, the recommended best practice for 
establishing a de novo reference interval (RI) is to enroll at least 120 reference 
individuals [69] and construct the RI using a simple nonparametric method.  When 120 
subjects who meet inclusion criteria cannot be obtained, other statistical approaches to 
determining a reference interval may be used and include traditional parametric, robust 
and bootstrap methods.  The Clinical and Laboratory Standards Institute recommends the 
use of the robust method, when less than 120 subjects can be obtained, as it does not 
require as many reference subjects as the nonparametric method and does not require the 
observed values to follow a Gaussian distribution.  There is no recommended minimum 
number of reference subjects when using the robust method but as the sample size 
decreases, the confidence intervals around the reference interval limits will increase, 
introducing uncertainty.  Therefore, if 120 observations are not possible, as many 
observations as possible should be collected to minimize uncertainty.  The Clinical 
Laboratory and Standards Institute is “hesitant to recommend” using even the robust 
method when less than 80 reference individuals can be obtained.  A study supporting this 
recommendation was published in 2009 by Geffre et al [105].  In that study, twenty 
randomly selected subsets (with n=27) were selected out of a larger population of 1439 
canines and RIs were calculated (for plasma creatinine) using the recommended robust 
method after transformation to a Gaussian distribution.  These small, subset RIs were 
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compared to the RI for the complete set and were sometimes found to be “grossly 
erroneous.”  For this reason, the authors concluded that all values should be reported 
graphically (in a dot plot or histogram) for small sample sizes.     
 
Another reason reference intervals were not established in the current study is because no 
attempt was made at true randomization of samples collected from the healthy 
cynomolgus macaques; instead we maximized the contribution of healthy animals already 
screened and enrolled in an islet transplantation study.   
 
Data presented here suggest that intra animal variability in cytokine concentration may be 
significant.  Replicate samples were analyzed, when present (n=11 animals), to determine 
the average CV and average absolute fold-change per animal.  The intra-animal CVs 
ranged from 16% to 86% and the fold change ranged from 1.3 to 19.1.  These data are 
provided in Appendix E for illustration purposes.  This variability exceeds the average 
inter-assay CV (<15% for all cytokines except TNFα with an intra-assay CV of 45%), 
leading to the conclusion that the variations seen in monkeys tested over time are not 
simply an artifact of normal assay variation, but rather stem from  biological variation.  A 
sample size of only two observations per animal gives a general confidence level of 62-
80%.  To determine true intra-animal variability with 95% confidence, a minimum of 15 
observations per animal would be needed (using broad assumptions of a population of 
1000 and a confidence interval of 25 pg/mL).  A large degree of inter-individual [106] 
and intra-individual [81] variability in cytokines among healthy populations has been 
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reported (IL-1ra ranging from undetectable levels to >1,500 pg/mL in similarly aged 
people, for example [106]).  Klein et al [107] suggests that meaningful results may need 
to be individualized (establishing a baseline “normal” for each individual before 
comparing to diseased states) because of the large amount of variation seen between 
individuals.  If such variability is normally present, population based RI will be very wide 
and potentially useless for detecting significant changes.  If a reference interval is large 
enough to encompass the normal inter-individual variability it may be insensitive to 
significant intra-individual variations [108].  Therefore, a test result within the 
population-based reference interval may be abnormal for that particular individual.  In 
cases like this, a subject-based RI may be more appropriate.  It is possible to determine 
mathematically whether a population- based or subject- based RI should be used for 
specific analytes by calculating the ‘index of individuality’ [109].  The index of 
individuality is determined using a simple calculation:  
(CVI2 + CVA2)1/2/ CVG 
Where CVI  is the individual, or, intra-subject variation (as a coefficient of variation), 
CVA is the analytical variation and CVG and is the group, or, inter-subject variation.  In 
the study reported here, the calculation of analytical variation has been performed.  The  
important next step is to investigate the intra- and inter-animal variability of these 
cytokines in healthy cynomolgus macaques to complete the equations that will help 
determine whether population-or subject-based RI are the most effective way to evaluate 
cytokine data in this species.  
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Because many cytokines act in an autocrine or paracrine manner, it may be of interest to 
understand cytokine concentrations in specific microenvironments.  For example, 
pancreatic islet cells are sometimes placed under the renal capsule of transplant 
recipients.  It could be useful to understand how cytokine concentrations may be affecting 
the outcome of graft placement in that specific location.  Likewise, peritoneal fluid, bone 
marrow or liver may also be sites of interest.  Procuring usable samples from these sites 
would, of course, be more difficult than a simple blood draw.  However, it is possible that 
less variability would be observed in microenvironments than has been shown 
systemically since fluctuations at other sites throughout the body would have a limited 
impact.  It would be important to validate the assay for use in any of these 
microenvironments as the different matrices may alter assay results.  Baseline sampling 
of these microenvironments would be necessary to interpret changes after transplantation.  
 
Limitations of the study 
There are study limitations to consider in this work.  In order to maximize useful data 
from an animal cohort enrolled in an islet transplantation study, true randomization of 
animals was not possible.  Therefore, the cytokine distributions presented represent a 
well-defined cohort of captive cynomolgus macaques rather than a description of the 
population.  As mentioned previously, a magnetic bead kit was used for the validation 
studies while a polystyrene bead kit was used to test samples from the 36 NHPs.  
However, 22 of the 23 antibody pairs were identical (other than IL-10) in both kits so it is 
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likely that similar results would be obtained using both kits.  Previous studies have 
suggested that the best use of multiplexed kits, where a loss of accuracy is generally 
offset by an abundance of data, may be in monitoring trends rather than describing 
absolute values.  If that is the case then the best use of this kit may be in comparing 
healthy to diseased states of animals. The data collected in this study was from healthy 
cynomolgus macaques so conclusions cannot be made about the performance of this kit 
in comparing changes from healthy to diseased states, or vice versa.  Rather the 
conclusions found in this study are related only to the performance of this kit in serum 
from healthy cynomolgus macaques.  Lastly, although the data presented here suggest 
that intra animal variability in cytokine concentration may be significant, it was not 
possible to make confident conclusions related to this within-animal cytokine variability 
due to the limited number of replicate samples from individual animals.   
 
Conclusions 
The results reported here demonstrate that the Millipore multiplex method can be used to 
reliably measure the following cytokines: TGFα, IFNγ, IL-2, IL-15, IL-13, IL-5, IL-6, IL-
8, MCP-1, IL-12/23(p40) and VEGF.  It can also be used for the cytokines that were 
found to be ‘marginally accepted’ (G-CSF, IL-10, sCD40L, IL-4 and MIP-1α) if the 
consistency limitations are kept in mind.  Data for seven cytokines has been found to be 
unreliable based on their inability to meet acceptance criteria (GM-CSF, IL-17A, IL-1ra, 
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IL-1β, TNFα, MIP-1β and IL-18).  The ability of the method to detect cytokine 
concentrations in healthy cynomolgus macaques has also been confirmed. 
 
This thesis described the error associated with the Millipore Milliplex NHP cytokine 
assay which demonstrated that seven out of 23 cytokines included in the panel did not 
meet pre-established acceptance criteria.  This validation ensures that the collection of 
inaccurate data, the determination of erroneous research conclusions, and the 
dissemination of unreliable research are minimized.  Data presented here will be 
communicated to researchers using this kit to monitor cytokine status in healthy 
cynomolgus macaque serum.  However, our role is to establish the error associated with 
this assay and communicate these results, not to enforce how a researcher decides to use 
this information in her own study.  Limited data describing serum cytokine 
concentrations are available in healthy cynomolgus macaques. However, this thesis 
included the reliable measurement of 16 cytokines in serum from 36 healthy animals.  
This work determined that significant cytokine variability exists within and between 
individual animals and provides a stepping stone for future work in establishing 
population- or subject-based reference intervals for cynomolgus macaques. 
 
Recommendations for using this method include: 
• Each animal should act as its own control since there appears to be a high degree 
of variability between animals.   
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• Repeated samples from individual animals may be of use as individual cytokines 
may vary widely in animals.  Repeat sampling should be done at regular intervals 
and at the same time of day to avoid confounding diurnal variation. 
• Validation should be completed for each sample type (serum, peritoneal fluid, 
synovial fluid, etc.) that will be tested in order to account for the potential of 
significant matrix effects. 
 
Thesis Summary   
Cytokines are a complex network of highly related proteins that regulate processes such 
as inflammation, basal immune function and cell growth and development.  If cytokines 
are to be measured and used to make conclusions on research studies, we must 
understand the variability around the measurement and the potential for errors associated 
with laboratory testing.  As methods become available we must evaluate their 
performance before we use them to make research conclusions.  Method validation 
procedures generate data that reflect assay performance and identify the inherent 
measurement uncertainty, allowing data to be accurately interpreted.  This study included 
the design and performance of a multiplex assay validation assessment for the 
simultaneous measurement of 23 cytokines in NHP serum.  The validation included 
analysis of serum samples from 36 healthy cynomolgus macaques in order to determine if 
the method could be used to detect cytokine concentrations in healthy NHP.  Although 
sensitivity and precision data were generally acceptable, recovery and linearity data were 
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highly variable.  Of the 23 cytokines tested, 11 met acceptance criteria, 5 were marginal 
and 7 were rejected.  If the validation studies had not been performed, false conclusions 
could be made (overestimated or underestimated cytokine values) contributing to errors 
within the Total Testing Process.  It is clear after performing this validation study, that 
clinical and research investment in multi-analyte methods is not warranted without 
demonstration of method validity for each analyte of interest. 
 
The validity of the multiplex method for analysis of specific cytokines in serum has been 
confirmed and the ability of the method to detect cytokine concentrations in healthy 
cynomolgus macaques has also been demonstrated.  Therefore, the potential for 
analytical error due to use of an un-validated method has been reduced for these analytes.  
It would be appropriate to continue to evaluate the performance of this method in 
alternate matrices (saliva, urine, peritoneal fluid, bone marrow) or in the current matrix 
(serum) with a protease inhibitor.  In addition, studies should be designed to evaluate the 
impact of pre-analytical error (e.g. storage time and temperature, blood collection and 
centrifugation steps) on the measurement of cytokines in serum from cynomolgus 
macaques.  Because this work demonstrates significant variability among measurements 
within and between animals, other important next steps include the description of typical 
variation levels within and between animals, followed by the generation of appropriate 
(population- or subject-based) reference intervals for healthy animals.   
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Although there are clearly some issues to be considered when validating and using 
multiplex assays, they are likely to remain an attractive option for researchers so it is in 
our best interest, as a scientific community, to understand and share data on assay 
performance.  
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Appendix A: Definitions and Summaries of the 23 Cytokines Studied 
 
One cytokine subset, interleukins, was originally named for their ability to mediate 
actions between leukocytes.  Interleukins have since been found to be produced by and to 
act on many different cell types beyond leukocytes.  Interleukin 2 (IL-2) is produced by 
and acts primarily on T lymphocyte cells (T cells) produced in the thymus.  After T cells 
are antigenically stimulated they release IL-2 which aids in generating cytotoxic and 
regulatory T cells, helping to prevent overstimulation of the immune response [110].  IL-
2 is necessary for the activation-induced cell death of T cells via the Fas ligand.  The 
activation of this pathway induces apoptosis, eliminating autoreactive T cells, thus aiding 
in the prevention of autoimmune diseases [111].  It has been observed that 50% of IL-2 
deficient mice die within 4-9 weeks of birth and the remaining mice develop an 
autoimmune disease resembling human ulcerative colitis, and express antibodies against 
self [112].  IL-2 is also stored in resting eosinophils at a concentration of 6 ± 2 
picograms/ 1 million cells and can be released within minutes after eosinophil stimulation 
[113].   
 
Tumor necrosis factor alpha (TNFα) was named appropriately after it was observed the 
protein was able to induce cell death in tumors.  Low levels of TNFα are important in 
normal tissue remodeling but high levels of TNFα can have negative and potentially fatal 
effects, such as toxic shock and sepsis [113], [114].  TNFα can be produced by many 
different cells, both immune and non-immune: macrophages, neutrophils, natural killer 
cells, osteoblasts, neurons and smooth muscle cells, to name a few. The most potent 
stimulus for TNFα activation is lipopolysaccharide (LPS); ultraviolet light also stimulates 
TNFα production in epithelial cells.  TNFα mRNA can be detected 15-30 minutes after 
stimulation even though no de novo synthesis is needed, suggesting that TNFα is not 
stored in cells but perhaps the precursors necessary for its production are [5], [115].  
Cytokine messages are known for being labile [116] and the half-life for TNFα mRNA is 
a brief 30 minutes [117] (half-lives of human mRNA less than two hours have been 
described as “fast” [118])  In addition, fully formed TNFα is also particularly unstable 
with a reported half-life of 18.2 minutes in human blood [119], [120], for comparison, 
thyroid hormones have a half-life of about one week in humans and the p35 subunit of 
IL-12 has a half-life of two to three hours.  
 
Interleukin 18 (IL-18) is a constitutively expressed proinflammatory cytokine that was 
previously known as IFNγ-inducing factor.  IL-18 works synergistically with IL-12 to 
induce Th1 cytokines like IFNγ, leading to release of tissue damaging molecules like 
nitric oxide and reactive oxygen species to fight bacterial infections [121].  IL-18 or IL-
12 alone will only modestly induce IFNγ, but when combined, their ability to induce 
IFNγ is significantly enhanced [122].  In the absence of IL-12, however, IL-18 induces a 
Th2 cytokine response, stimulating cytokines like IL4 and IL-13. 
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Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis (the 
formation of new blood vessels).  The ability of VEGF to stimulate angiogenesis is 
necessary for wound healing, menstruation, normal development and growth in the 
corpus luteum [123], fetal eye development [124] and bone development [125], for 
example.  VEGF also plays important roles in many diseases because of its ability to 
stimulate vascular invasion.  Tumor cells cannot survive without adequate blood supply 
making angiogenesis integral to survival past a certain tumor volume threshold.  Arthritis 
[126], diabetic retinopathy [127] and psoriasis [128] also rely on angiogenesis via VEGF 
for at least part of their pathogenesis.  VEGF is stimulated by hypoxia, especially in 
tumor cells, due to increased mRNA stability under oxygen-poor conditions [129].  
Inflammatory cytokines such as IL-6 and TNFα also stimulate the release VEGF [130], 
linking chronic inflammation with angiogenesis and cancer.   
 
Interleukin 8 (IL-8) is a proinflammatory cytokine first observed in 1987 for its ability to 
act as a neutrophil chemoattractant [94].   IL-8 is produced by many different cells, 
including T cells, neutrophils, NK cells, fibroblasts, epithelial cells and tumor cells.  IL-8 
can be induced by other proinflammatory cytokines (IL-1, TNFα) [131], bacteria [132], 
[133] and viral infection [134], [135].  Similar to VEGF, IL-8 is also induced by hypoxia 
[136] and can act as an angiogenic factor [137].   
 
There are 3 classic members of the IL-1 family: IL-1α, IL-1β and IL-1ra.  Although IL-
1α and IL-1β are structurally similar, bind to the same cell surface receptor and have 
similar functions, they only show about 25% amino acid homology [138].  IL-1β is a 
proinflammatory cytokine that is generally not produced in healthy human cells until 
challenged with bacterial or viral infections at which time it moderates the acute phase 
response.  Even small amounts of IL-1β will cause a drop in blood pressure, raise the 
internal body temperature and induce production of IL-6, leading to synthesis of acute 
phase proteins from the liver [8].  IL-1 has been shown to be important in carcinogenesis 
and IL-1β was found to induce transcriptional activation of breast cancer cells via 
estrogen receptor alpha [139].  Interleukin 1 receptor antagonist (IL-1ra) passively 
inhibits the inflammatory cytokine IL-1 by binding to the IL-1 receptor and blocking IL-1 
binding [140].  The production of IL-1ra from monocytes and macrophages is stimulated 
by IgG binding, GM-CSF and IL-1.  Human recombinant IL-1ra is produced 
commercially under the name anakinra and is used to treat rheumatoid arthritis symptoms 
by decreasing inflammation [141].   
 
Interleukin 4 (IL-4) and interleukin 13 (IL-13) share several features including 
immunoglobulin (Ig) isotype switching to IgE. In fact, mice deficient in both IL-4 and IL-
13 had undetectable levels of circulating IgE [92].  Due to their integral role in IgE 
production, these cytokines are important in type I hypersensitivity and allergic 
conditions.  Although IL-4 and IL-13 only exhibit about 30% amino acid sequence 
homology [142], their related functions are partly due to a shared receptor system [143].  
IL-13 and IL-4 are secreted by T cells, mast cells and basophils, while IL-13 is 
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additionally secreted by natural killer (NK) cells, smooth muscle cells and eosinophils.  
IL-13 appears to be necessary for the expulsion of gastrointestinal parasites while IL-4 is 
not [144].  The anti-tumor effects of IL-4 are currently under examination as the cytokine 
seems to show conflicting roles in tumor development.  Originally IL-4 seemed to show a 
clear anti-tumor role [145], [146], but when therapeutic IL-4 was studied in a clinical 
human cancer trial, the results did not support the proposed role of IL-4 [147] and 
indicated that IL-4 may instead be exacerbating the problem.  It was later found that 
tumors would only grow in mice with functional IL-4 [148] and additionally, that IL-4 
seemed to promote tumor metastasis [149].  Further investigation into the tumor-
development role of IL-4 in will undoubtedly continue.  
 
Interleukins 12 and 23 are both heterodimers that have a p40 subunit in common, while 
IL-12 has a unique p35 subunit and IL-23 has a unique p19 subunit.  This shared p40 
subunit is produced independently from both the p35 and p19 subunits; it can be secreted 
and can function independently (as a monomer, p40, or as a homodimer, p80) [150] or in 
conjunction with its respective partner subunit.  IL-12 and IL-23 are both expressed by 
dendritic cells and macrophages, while IL-12 is also produced by B cells [151].  The p40 
subunit is important in the inflammatory pathway and has been observed to act as an 
antagonist to both IL-12 and IL-23 by competitively binding to the same receptor and 
blocking IL-12/23 responses [97], [152].  When released as a homodimer this cytokine is 
a chemoattractant for macrophages [153], an inducer of dendritic cell migration to the 
lymph node [154], and a suspect in allograft rejection, partly due to its ability to induce 
IFNγ [155].   
 
The colony stimulating factors, granulocyte-macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF) are both inducers of 
hematopoietic cell development and migration of stem cells from the bone marrow to 
circulation.  Both cytokines are known to be potent stimulators of  neutrophilic activity 
[156], [157].  Unlike G-CSF, GM-CSF has also been shown to increase phagocytosis by 
macrophages [158], promote dendritic cell development [159], and promote eosinophil 
development and adhesion [160] as it is directed toward a population of progenitor cells 
earlier in development than G-CSF.  Both cytokines can be produced by several different 
cell types including, macrophages, endothelial cells, fibroblasts and stromal cells, while 
GM-CSF has also been shown to be produced by T cells, NK cells and respiratory 
epithelial cells, among others [5].  Both G-CSF and GM-CSF have been approved by the 
FDA to treat neutropenia (low neutrophil counts) in patients, especially after bone 
marrow transplant or chemotherapy [161], [162].   
 
Cytokines known as interferons (IFNs) protect against viral and bacterial infection and 
are classified by two types: type I include IFN-alpha (IFNα) and IFN-beta (IFNβ), and 
both respond to viral infection [163]; type II IFN is known as IFN-gamma (IFNγ) and is 
activated after NK cells or T lymphocytes are activated with a non-viral inflammatory 
agent [164].  IFNγ up-regulates the expression of MHC class II on antigen presenting 
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cells and is a Th1 cytokine that activates NK cells, cytotoxic T cells and macrophages.  
IFNγ is also important for anti-tumor activity via two routes; non-immunologic actions 
like inhibiting angiogenesis and proliferation and promoting apoptosis, and immunologic 
actions like activating macrophages.  Furthermore, recent research suggests that IFNγ 
may affect certain tumor cell genes making the tumor more immunogenic [165].   
 
Interleukin 5 (IL-5) is produced primarily by Th2 cells [166] and is known predominantly 
for promoting the growth of eosinophils [167].  Due to the role eosinophils play, IL-5 
indirectly effects helminth immunity, allergies and asthma.   IL-5 was suspected to be 
important for B cell development as it was observed that murine B cells in the peritoneal 
cavity constitutively expressed IL-5 receptors [168].  Although many studies have 
demonstrated the interaction between IL-5 and B cells in vitro, the in vivo effects seem to 
be minimal in both humans and mice.  IL-5 knockout mice show very little adverse 
effects in regards to B cells, other than delayed B cell development [5], [169].  The role 
of IL-5 in human B cell development also seems to be less important than originally 
suspected as little or no effect of IL-5 on human B cells was seen in several experiments 
[170], [171].  
 
Interleukin 6 (IL-6) was first observed in 1985 as a factor that helped stimulate and 
differentiate antigen-activated B cells into plasma cells [172].  IL-6 is produced in 
response to many different stimuli, including bacterial and viral infection, other 
proinflammatory cytokines, and UV exposure. After IL-6 was found to be involved in 
several inflammatory diseases, such as rheumatoid arthritis (RA)  [173] and Chrohn’s 
disease, an anti-IL-6-receptor antibody was approved for use in RA patients by the FDA 
[174].  IL-6 is important in the synthesis and release of acute phase proteins [175] and 
has been shown to stimulate the release of adrenocorticotrophic hormones [176], 
prolactin, growth hormone and luteinizing hormone [177].  IL-6 is produced by many 
cells including macrophages, dendritic cells, mast cells, B cells, T helper cells, fibroblasts 
and epithelial cells. 
 
Interleukin 15 (IL-15) has similar effects to IL-2 and both cytokines use the same IL-2 
receptor subunits for signal transduction, however, while IL-2 aids in T cell development 
within the thymus, IL-15 promotes development of T and NK cells outside of the thymus 
[178].  IL-15 is mainly produced by activated macrophages and muscle cells but is also 
produced to a lesser extent by keratinocytes, dendritic cells and by placental tissues, 
among others, but is not produced by activated T cells, which are the sole source of IL-2.  
IL-15 also stimulates the proliferation of activated B cells but has no effect on resting B 
cells [179].   
 
Interleukin 17A (IL-17A) is a proinflammatory cytokine that recruits neutrophils and 
monocytes and induces the release of other cytokines such as TNFα, IL-1β and IL-6 from 
macrophages [180] making it important in defending against infection.  IL-17A is also 
known as IL-17 or CTLA8 in rodents and is produced by Th17 cells [181].  Although IL-
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17A is important in defending against infection, it can be harmful in high concentrations 
and has been implicated in lung damage after flu infection due to extensive neutrophil 
recruitment [182].  Furthermore, IL-17A is likely involved in transplant rejection as it has 
been detected in transplant environments during graft rejection where it was previously 
absent [183]. 
 
Since proinflammatory cytokines can cause damage (cell death) at high concentrations, 
interleukin 10 (IL-10) has the job of keeping those potentially harmful cytokines in 
check.  IL-10 can inhibit the synthesis of IL-2 and IL-5 from T cells [184] and IL-1, IL-6, 
IL-8, IL-12 and TNFα from monocytes and macrophages [185].  Another important role 
for IL-10 is its ability to induce differentiation and proliferation of B cells [186].  This 
cytokine is produced by many cells types but most predominantly by monocytes, 
macrophages and T cells.  B cells also produce IL-10 where it acts in an autocrine 
manner to prevent apoptosis [187].  
 
Transforming growth factor alpha (TGFα) was first discovered in sarcoma virus-infected 
fibroblasts in 1978 [188] and was later discovered to be an embryonic growth factor that 
was abnormally expressed in neoplasms [189].  Aside from its role in normal embryonic 
and organ development, it is also important for wound repair, bone reabsorption and 
angiogenesis.  Biological sources of TGFα include keratinocytes, airway epithelial cells, 
pituitary, mucosal tissues and eosinophils, among others.  Despite its important role in 
normal development, TGFα is most well-known for its role in cancer.  TGFα is thought 
to self-promote growth of tumor cells via the endothelial growth factor receptor (EGFR) 
on the tumor cell surface [190].   
 
As the name suggests, monocyte chemotactic protein 1 (MCP-1), also known as CCL2, is 
recognized for its ability to attract monocytes, which becomes especially important at 
inflammation sites.  Blocking MCP-1 has been shown to suppress delayed-type 
hypersensitivity [191], inflammatory arthritis [192] and shock due to endotoxins [193], 
delineating its role in inflammation but also pointing to its potential for negative effects.  
MCP-1 is produced by monocytes, fibroblasts, vascular smooth muscle cells, endothelial 
cells and mast cells.  
 
Similar to MCP-1, the macrophage inflammatory proteins (MIP) are also monocyte 
chemoattractants. There are two members of the MIP family, MIP-1α, also known as 
CCL3 and MIP-1β, also known as CCL4, both are produced by macrophages.  Both MIPs 
can attract T lymphocytes while MIP-1α can also attract B cells [194], eosinophils and 
basophils; MIP-1α not only attracts these cells but can cause degranulation of eosinophils 
and histamine release from basophils and mast cells [195].  MIP-1α has been shown to 
inhibit the proliferation of hematopoietic stem cells [196].  The metabolic hormone leptin 
can enhance MIP-1α and MIP-1β production in murine macrophages in vitro [197].    
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The interaction between the cell surface receptor CD40 and its ligand CD40L (also 
known as CD154) plays a critical role in the activation of B cells and subsequent release 
of immunoglobulins.  It was originally thought that cell-cell contact via CD40 on B cells 
with CD40L on activated T cells was necessary for B cell activation through this 
receptor, however it was discovered that a soluble form of CD40L (sCD40L) can be 
cleaved from the membrane-bound ligand and produce the necessary activation signal 
[198].  Platelets can also express both a membrane-bound and a soluble version of 
CD40L.  Deficiency of CD40L prevents B cells from undergoing class switch and results 
in the immunodeficiency disease hyper-IgM syndrome [199].  
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Table 10: Summary of the 23 cytokines measured using the Multiplex assay.  
Abbreviations: B: B cell; Baso: Basophil; EOS: Eosinophil; En: Endothelial cell; Epi: Epithelial 
cell; DC: Dendritic cell; FB: Fibroblast; KC: Keratinocyte; T: T cell; Th2: type 2 T helper; Treg: 
regulatory T cell; M: Macrophage; MC: Mast cell; Mo: Monocyte; Neu: Neutrophil; NK: natural 
killer cell; VSM: Vascular smooth muscle 
Cytokine Major Role(s) Produced By 
Observed 
Concentration 
Ranges in Human 
Sera* (n=20) 
GM-CSF 
Growth and 
differentiation of 
hematopoietic cells 
T, B, FB, En, M <3.2 – 756 pg/mL (50% detectable) 
TGFα Embryonic development, wound repair, neoplasia EOS, KC, mucosal cells 
<3.2 – 53.9 pg/mL 
(45% detectable) 
G-CSF Growth and development of Neu M, En, FB, stromal cells 
<3.2 – 22.2 pg/mL 
(60% detectable) 
IFNγ 
Primary cytokine 
responsible for cell-
mediated immunity 
Activated T, NK <3.2 – 32.7 pg/mL (80% detectable) 
IL-2 Proliferation and regulation of T cells CD4
+ T <3.2 – 30 pg/mL (25% detectable) 
IL-10 Anti-inflammatory; inhibits Mo and M M, Th2, Treg 
<3.2 – 102 pg/mL 
(55% detectable) 
IL-15 T and NK proliferation M, muscle cells <3.2 – 10.7 pg/mL (75% detectable) 
sCD40L B cell activation, class switch, Ig release CD4+ T, platelets 
<3.2 – 403 pg/mL 
(70% detectable) 
IL-17A Proinflammatory; Neu recruitment Th17 
<3.2 – 10 pg/mL 
(95% detectable) 
IL-1ra Inhibits IL-1 activity Mo and tissue M <3.2 – 156 pg/mL (55% detectable) 
IL-13 IgE production, expulsion of GI parasites 
EOS, Baso; T, NK, MC, 
smooth muscle cells  
<3.2 – 16.8 pg/mL 
(20% detectable) 
IL-1β 
Proinflammatory; 
moderates acute phase 
response 
Activated M <3.2 – 27.9 pg/mL (30% detectable) 
IL-4 IgE production T, MC, Baso <3.2 – 362 pg/mL (55% detectable) 
IL-5 EOS production Th2, EOS, MC <3.2 – 14.9 pg/mL (70% detectable) 
IL-6 
Proinflammatory; B cell 
differentiation; release of 
acute phase proteins 
Many, incl. M, DC, MC, 
B 
<3.2 – 39 pg/mL 
(80% detectable) 
IL-8 Proinflammatory; Neu chemoattractant 
Many, incl. T cells, 
neutrophils, NK cells, 
fibroblasts, epithelial 
cells,  tumor cells 
<3.2 – 81.8 pg/mL 
(60% detectable) 
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 MIP-1α Chemoattractant for Mo, T, B, EOS, Baso M 
<3.2 – 1510 pg/mL 
(70% detectable) 
MCP-1 Mo chemoattractant Mo, FB, VSM, En, MC 63.5 – 439 pg/mL 
TNFα Mediates inflammatory reactions 
Many; Activated M, 
Neu, T, B, NK 
<3.2 – 6.4 pg/mL 
(5% detectable) 
MIP-1β Mo and T chemoattractant M 
<3.2 – 118 pg/mL 
(85% detectable) 
IL-12/23(p40) 
M chemoattractant; IFNγ 
synthesis; IL-12 
antagonist 
DC, M, B <3.2 – 406 pg/mL (30% detectable) 
VEGF Stimulates angiogenesis Many; incl. Neu, M, adipose tissue, En, VSM 
<3.2 – 118 pg/mL 
(75% detectable) 
IL-18 
Proinflammatory; T and 
NK maturation; IFNγ 
stimulation 
Several; Incl. M, DC, 
osteoblasts, KC, 
intestinal epithelium 
** 36.1 – 258 pg/mL 
(n=46) 
*All human cytokine concentration data except for IL-18 provided by Millipore as obtained from 
their Milliplex MAP Human Cytokine/Chemokine 42-plex panel (catalog number MPXHCYTO-
60K) [73]. 
**Human IL-18 concentration data provided by R&D Systems as obtained by their IL-18 
Quantikine ELISA 
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 Appendix B: Additional Materials and Methods 
 
Table 11: Summary of protein and antibody sources in the Multiplex cytokine assay kit 
used.  
Cytokine 
Protein Source 
for Standard 
and Control 
Species Detection 
antibody was 
raised against 
IFNγ, IL-1β, IL-4, IL-5, IL-12/23(p40), IL-13, 
TNFα, IL-18 
Recombinant  
NHP Human 
IL-2 Recombinant  
NHP 
NHP 
VEGF Human Mouse 
G-CSF, GM-CSF, IL-1ra, IL-6, IL-8, IL-10, 
IL-15, IL17A, MCP-1, MIP-1α, MIP-1β, 
sCD40L, TGFα 
Human Human 
 
 
Table 12: Summary of assay controls used in all NHP cytokine assays performed. 
QC 1 Manufacturer provided Reconstituted with nanopure water prior to each assay, 
according to manufacturer instructions (0.25mL water) 
QC 2 Manufacturer provided Reconstituted with nanopure water prior to each assay, 
according to manufacturer instructions (0.25mL water) 
QC 3 NHP pool + diluted QC 1 QC 1 was diluted to 25% with assay buffer and mixed 
in equal volume with the NHP pool* 
QC 4 NHP pool + diluted QC 2 QC 2 was diluted to 25% with assay buffer and mixed 
in equal volume with the NHP pool* 
*NHP Pool was made by combining serum from 2 healthy cynomolgus macaques, collected on 
the same day and kept frozen at -20oC until the day of assay. 
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 Figure 7: Plate layouts used for all validation assays performed. 
 
Validation Plate 1: 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
QC1 QC1 QC1 Precision [high] 
Precision 
[high] 
Precision 
[high] 
Linearity: 
(sample 1 
+ Std 7) at 
20% 
Linearity: 
(sample 1 
+ Std 7) at 
20% 
Linearity: 
(sample 1 
+ Std 7) at 
20% 
B Standard 1 
Standard 
1 
Standard 
1 QC2 QC2 QC2 
Precision 
[high] 
Precision 
[high] 
Precision 
[high] 
Sample 2 
neat 
Sample 2 
neat 
Sample 2 
neat 
C Standard 2 
Standard 
2 
Standard 
2 QC3 QC3 QC3 
Precision 
[high] 
Precision 
[high] 
Precision 
[high] 
Recovery: 
Sample 2 
+ Std 7 
Recovery: 
Sample 2 
+ Std 7 
Recovery: 
Sample 2 
+ Std 7 
D Standard 3 
Standard 
3 
Standard 
3 QC4 QC4 QC4 
Precision 
[high] 
Precision 
[high] 
Precision 
[high] 
Recovery: 
Sample 2 
+ Std 6 
Recovery: 
Sample 2 
+ Std 6 
Recovery: 
Sample 2 
+ Std 6 
E Standard 4 
Standard 
4 
Standard 
4 
Precision 
[low] 
Precision 
[low] 
Precision 
[low] 
Sample 1 
neat 
Sample 1 
neat 
Sample 1 
neat 
Linearity: 
(sample 2 
+ Std 7) at 
50% 
Linearity: 
(sample 2 
+ Std 7) at 
50% 
Linearity: 
(sample 2 
+ Std 7) at 
50% 
F Standard 5 
Standard 
5 
Standard 
5 
Precision 
[low] 
Precision 
[low] 
Precision 
[low] 
Recovery: 
Sample 1 
+ Std 7 
Recovery: 
Sample 1 
+ Std 7 
Recovery: 
Sample 1 
+ Std 7 
Linearity: 
(sample 2 
+ Std 7) at 
20% 
Linearity: 
(sample 2 
+ Std 7) at 
20% 
Linearity: 
(sample 2 
+ Std 7) at 
20% 
G Standard 6 
Standard 
6 
Standard 
6 
Precision 
[low] 
Precision 
[low] 
Precision 
[low] 
Recovery: 
Sample 1 
+ Std 6 
Recovery: 
Sample 1 
+ Std 6 
Recovery: 
Sample 1 
+ Std 6 
Sensitivity: 
Std 1 at 
50% 
Sensitivity: 
Std 1 at 
50% 
Sensitivity: 
Std 1 at 
50% 
H Standard 7 
Standard 
7 
Standard 
7 
Precision 
[low] 
Precision 
[low] 
Precision 
[low] 
Linearity: 
(sample 1 
+ Std 7) 
at 50% 
Linearity: 
(sample 1 
+ Std 7) 
at 50% 
Linearity: 
(sample 1 
+ Std 7) 
at 50% 
Sensitivity: 
Std 1 at 
50% 
Sensitivity: 
Std 1 at 
50% 
Sensitivity: 
Std 1 at 
50% 
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 Figure 7 Continued: Validation Plate 2 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
QC1 QC1 QC1 
Recovery: 
Sample 3 
+ Std 6 
Recovery: 
Sample 3 
+ Std 6 
Recovery: 
Sample 3 
+ Std 6 
Linearity: 
(sample 4 
+ Std 7) at 
50% 
Linearity: 
(sample 4 
+ Std 7) at 
50% 
Linearity: 
(sample 4 
+ Std 7) at 
50% 
B Standard 1 
Standard 
1 
Standard 
1 QC2 QC2 QC2 
Linearity: 
sample 3 
at 50% 
Linearity: 
sample 3 
at 50% 
Linearity: 
sample 3 
at 50% 
Linearity: 
(sample 4 
+ Std 7) at 
20% 
Linearity: 
(sample 4 
+ Std 7) at 
20% 
Linearity: 
(sample 4 
+ Std 7) at 
20% 
C Standard 2 
Standard 
2 
Standard 
2 QC3 QC3 QC3 
Linearity: 
(sample 3 
+ Std 7) 
at 50% 
Linearity: 
(sample 3 
+ Std 7) 
at 50% 
Linearity: 
(sample 3 
+ Std 7) 
at 50% 
Sample5 
(pool) 
neat 
Sample5 
(pool) 
neat 
Sample5 
(pool) 
neat 
D Standard 3 
Standard 
3 
Standard 
3 QC4 QC4 QC4 
Linearity: 
(sample 3 
+ Std 7) 
at 20% 
Linearity: 
(sample 3 
+ Std 7) 
at 20% 
Linearity: 
(sample 3 
+ Std 7) 
at 20% 
Recovery: 
Sample 5 
+ Std 7 
Recovery: 
Sample 5 
+ Std 7 
Recovery: 
Sample 5 
+ Std 7 
E Standard 4 
Standard 
4 
Standard 
4 
Sensitivity
: Std 1 at 
50% 
Sensitivity
: Std 1 at 
50% 
Sensitivity
: Std 1 at 
50% 
Sample 4 
neat 
Sample 4 
neat 
Sample 4 
neat 
Recovery: 
Sample 5 
+ Std 6 
Recovery: 
Sample 5 
+ Std 6 
Recovery: 
Sample 5 
+ Std 6 
F Standard 5 
Standard 
5 
Standard 
5 
Sensitivity
: Std 1 at 
50% 
Sensitivity
: Std 1 at 
50% 
Sensitivity
: Std 1 at 
50% 
Recovery: 
Sample 4 
+ Std 7 
Recovery: 
Sample 4 
+ Std 7 
Recovery: 
Sample 4 
+ Std 7 
Linearity: 
sample 5 
at 50% 
Linearity: 
sample 5 
at 50% 
Linearity: 
sample 5 
at 50% 
G Standard 6 
Standard 
6 
Standard 
6 
Sample 3 
neat 
Sample 3 
neat 
Sample 3 
neat 
Recovery: 
Sample 4 
+ Std 6 
Recovery: 
Sample 4 
+ Std 6 
Recovery: 
Sample 4 
+ Std 6 
Linearity: 
(sample 5 
+ Std 7) at 
50% 
Linearity: 
(sample 5 
+ Std 7) at 
50% 
Linearity: 
(sample 5 
+ Std 7) at 
50% 
H Standard 7 
Standard 
7 
Standard 
7 
Recovery: 
Sample 3 
+ Std 7 
Recovery: 
Sample 3 
+ Std 7 
Recovery: 
Sample 3 
+ Std 7 
Linearity: 
sample 4 
at 50% 
Linearity: 
sample 4 
at 50% 
Linearity: 
sample 4 
at 50% 
Linearity: 
(sample 5 
+ Std 7) at 
20% 
Linearity: 
(sample 5 
+ Std 7) at 
20% 
Linearity: 
(sample 5 
+ Std 7) at 
20% 
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 Figure 7 Continued: Validation Plate 3 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
QC1 QC1 QC1 
Linearity: 
(sample 6 
+ Std 7) 
at 20% 
Linearity: 
(sample 6 
+ Std 7) 
at 20% 
Linearity: 
(sample 6 
+ Std 7) 
at 20% 
Recovery: 
Sample 8 
+ Std 4 
Recovery: 
Sample 8 
+ Std 4 
Recovery: 
Sample 8 
+ Std 4 
B Standard 1 
Standard 
1 
Standard 
1 QC2 QC2 QC2 
Sample 7 
neat 
Sample 7 
neat 
Sample 7 
neat 
Recovery: 
Sample 8 
+ Std 3 
Recovery: 
Sample 8 
+ Std 3 
Recovery: 
Sample 8 
+ Std 3 
C Standard 2 
Standard 
2 
Standard 
2 QC3 QC3 QC3 
Recovery: 
Sample 7 
+ Std 7 
Recovery: 
Sample 7 
+ Std 7 
Recovery: 
Sample 7 
+ Std 7 
Linearity: 
(sample 8 
+ Std 75 
at 50% 
Linearity: 
(sample 8 
+ Std 75 
at 50% 
Linearity: 
(sample 8 
+ Std 75 
at 50% 
D Standard 3 
Standard 
3 
Standard 
3 QC4 QC4 QC4 
Recovery: 
Sample 7 
+ Std 6 
Recovery: 
Sample 7 
+ Std 6 
Recovery: 
Sample 7 
+ Std 6 
Linearity: 
(sample 8 
+ Std 5) at 
20% 
Linearity: 
(sample 8 
+ Std 5) at 
20% 
Linearity: 
(sample 8 
+ Std 5) at 
20% 
E Standard 4 
Standard 
4 
Standard 
4 
Sample 6 
neat 
Sample 6 
neat 
Sample 6 
neat 
Linearity: 
(sample 7 
+ Std 7) 
at 50% 
Linearity: 
(sample 7 
+ Std 7) 
at 50% 
Linearity: 
(sample 7 
+ Std 7) 
at 50% 
Sample 9 
(also run 
on old kit) 
Sample 9 
(also run 
on old kit) 
Sample 9 
(also run 
on old kit) 
F Standard 5 
Standard 
5 
Standard 
5 
Recovery: 
Sample 6 
+ Std 7 
Recovery: 
Sample 6 
+ Std 7 
Recovery: 
Sample 6 
+ Std 7 
Linearity: 
(sample 7 
+ Std 7) 
at 20% 
Linearity: 
(sample 7 
+ Std 7) 
at 20% 
Linearity: 
(sample 7 
+ Std 7) 
at 20% 
Sample 10 
(also run 
on old kit) 
Sample 10 
(also run 
on old kit) 
Sample 10 
(also run 
on old kit) 
G Standard 6 
Standard 
6 
Standard 
6 
Recovery: 
Sample 6 
+ Std 6 
Recovery: 
Sample 6 
+ Std 6 
Recovery: 
Sample 6 
+ Std 6 
Sample 8 
neat 
Sample 8 
neat 
Sample 8 
neat 
Sample 11 
(also run 
on old kit) 
Sample 11 
(also run 
on old kit) 
Sample 11 
(also run 
on old kit) 
H Standard 7 
Standard 
7 
Standard 
7 
Linearity: 
(sample 6 
+ Std 7) at 
50% 
Linearity: 
(sample 6 
+ Std 7) at 
50% 
Linearity: 
(sample 6 
+ Std 7) at 
50% 
Recovery: 
Sample 8 
+ Std 5 
Recovery: 
Sample 8 
+ Std 5 
Recovery: 
Sample 8 
+ Std 5 
Sample 12 
(also run 
on old kit) 
Sample 12 
(also run 
on old kit) 
Sample 12 
(also run 
on old kit) 
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 Figure 7 Continued: Validation Plate 4: (where (1) through (30) represent individual animal samples tested): 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
0 pg/mL 
Back-
ground 
QC1 QC1 QC1 (5) (5) (13) (13) (21) (21) 
B Standard 1 
Standard 
1 
Standard 
1 QC2 QC2 QC2 (6) (6) (14) (14) (22) (22) 
C Standard 2 
Standard 
2 
Standard 
2 QC3 QC3 QC3 (7) (7) (15) (15) (23) (23) 
D Standard 3 
Standard 
3 
Standard 
3 QC4 QC4 QC4 (8) (8) (16) (16) (24) (24) 
E Standard 4 
Standard 
4 
Standard 
4 (1) (1) (29) (9) (9) (17) (17) (25) (25) 
F Standard 5 
Standard 
5 
Standard 
5 (2) (2) (29) (10) (10) (18) (18) (26) (26) 
G Standard 6 
Standard 
6 
Standard 
6 (3) (3) (30) (11) (11) (19) (19) (27) (27) 
H Standard 7 
Standard 
7 
Standard 
7 (4) (4) (30) (12) (12) (20) (20) (28) (28) 
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 Appendix C: Additional Validation Results 
 
Table 13: Summary of quantitative precision data observed. For intra-assay precision n=24 in 
one assay.  For inter-assay precision n=4 (4 assays in which each control was tested in triplicate). 
In order to meet assay acceptance criteria, intra-assay precision is expected to be ≤ 20% and inter-
assay precision is expected to be ≤ 25%. 
Cytokine Intra-assay Precision Outcome 
Inter-assay 
Precision Outcome 
GM-CSF 2% Pass 9% Pass 
TGFα 4% Pass 4% Pass 
G-CSF 6% Pass 16% Pass 
IFNγ 2% Pass 7% Pass 
IL-2 1% Pass 6% Pass 
IL-10 2% Pass 6% Pass 
IL-15 2% Pass 9% Pass 
sCD40L 7% Pass 7% Pass 
IL-17A 1% Pass 15% Pass 
IL-1ra 3% Pass 15% Pass 
IL-13 1% Pass 8% Pass 
IL-1β 2% Pass 4% Pass 
IL-4 9% Pass 7% Pass 
IL-5 3% Pass 5% Pass 
IL-6 3% Pass 6% Pass 
IL-8 2% Pass 7% Pass 
MIP-1α 4% Pass 8% Pass 
MCP-1 3% Pass 6% Pass 
TNFα 6% Pass 45% Fail 
MIP-1β 4% Pass 10% Pass 
IL-12/23(p40) 2% Pass 11% Pass 
VEGF 4% Pass 12% Pass 
IL-18 8% Pass 14% Pass 
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Table 14: Results of quantitative recovery studies.  Seven individual animal samples and one 
NHP serum pool were spiked with known amounts of standard at various levels to yield 17 
separate spiked samples, each measured in duplicate, over 3 assays.  Each high and low accuracy 
shown here is the average of duplicates from one of the 17 spiked samples. In order to meet assay 
acceptance criteria, accuracy is expected to be 75% to 125% of expected values.  
Analyte Lowest Recovery 
Highest 
Recovery Median Mean Result 
Millipore 
Result 
GM-CSF 74% 585% 294% 307% Fail 99% 
TGFα 8% 204% 81% 82% Pass 98% 
G-CSF 38% 95% 74% 71% Fail 93% 
IFNγ 36% 120% 77% 75% Pass 92% 
IL-2 55% 139% 91% 93% Pass 90% 
IL-10 23% 113% 57% 67% Fail 101% 
IL-15 53% 113% 82% 83% Pass 93% 
sCD40L 43% 108% 87% 86% Pass 90% 
IL-17A 8% 78% 57% 47% Fail 93% 
IL-1ra 27% 130% 50% 58% Fail 90% 
IL-13 32% 131% 78% 79% Pass 90% 
IL-1β 27% 115% 61% 63% Fail 91% 
IL-4 0% 67% 45% 45% Fail 94% 
IL-5 57% 136% 109% 106% Pass 96% 
IL-6 48% 237% 125% 118% Pass 87% 
IL-8 50% 143% 96% 91% Pass 89% 
MIP-1α 14% 152% 63% 65% Fail 89% 
MCP-1 63% 252% 102% 106% Pass 90% 
TNFα 17% 139% 69% 96% Fail 96% 
MIP-1β 2% 101% 53% 44% Fail 90% 
IL-12/23(p40) 36% 125% 84% 82% Pass 95% 
VEGF 55% 110% 88% 86% Pass 70% 
IL-18 2% 31% 23% 20% Fail 91% 
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Table 15: Summary of quantitative linearity studies of neat samples and samples spiked with the 
highest assay standard. 
Cytokine 
Linearity of 
neat samples 
(n=3) 
Lin of spiked 
samples 
(n=16) 
GM-CSF < range 166% 
TGFα 91% 235% 
G-CSF 62% 172% 
IFNγ 112% 128% 
IL-2 119% 116% 
IL-10 100% 151% 
IL-15 82% 120% 
sCD40L 126% 148% 
IL-17A 126% 193% 
IL-1ra 163% 181% 
IL-13 98% 95% 
IL-1β < range 139% 
IL-4 248% 111% 
IL-5 33% 132% 
IL-6 55% 112% 
IL-8 125% 110% 
MIP-1α 251% 120% 
MCP-1 105% 99% 
TNFα 71% 162% 
MIP-1β 125% 306% 
IL-12/23(p40) 107% 151% 
VEGF 114% 151% 
IL-18 87% 225% 
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 Appendix D: Non-Human Primate Data for Rejected Cytokines 
 
To discourage the interpretation of data from cytokines that have proven inaccurate, data 
from the rejected cytokines was not included with results presented earlier.  It is 
presented here for informational purposes only.   
 
The range, median and percentage of NHP samples within the detection limits of the 
assay are shown for each cytokine in Table 16.   
 
Table 16: Summary of cytokine ranges and percent detectable for the rejected cytokines when 
tested in 36 individual animals (averages were calculated for animals with multiple samples). 
Analyte Range 
(pg/mL) 
Median % of samples within 
working range of assay 
GM-CSF <0.64 - 647 15.4 72% 
IL-1ra <0.64 - 36 <0.64 17% 
IL-1β <0.64 - 3.5 <0.64          8% 
IL-17A <0.64 - 42 <0.64 50% 
MIP-1β <0.64 - 20 2.4 81% 
TNFα <0.64 - 193 2.7 75% 
IL-18 <0.64 - 335 42.9 89% 
 
 
Table 17 shows how the NHP data obtained in this study compares to a normal range in 
human serum.  Figure 8 shows the percent of samples tested form humans and NHPs that 
are within the detectable ranges. 
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Table 17: Comparison of cytokine concentrations in human and NHP sera for the rejected 
cytokines. All human data were provided by Millipore and the NHP data were found in this study.  
The percent of samples within the working range of the assay is shown if any samples fell outside 
the detectable limits. 
Cytokine Concentration Range in 
Human Sera (pg/mL)* 
Observed Concentration Range 
in NHP Sera (pg/mL) 
GM-CSF <3.2 – 53.9 (45% detectable) <0.64-647 (72% detectable) 
IL-1ra <3.2 – 30 (25% detectable) <0.64-36 (17% detectable) 
IL-1β <3.2 – 32.7 (80% detectable) <0.64-3.5 (8% detectable) 
IL-17A <3.2 – 39 (80% detectable) <0.64-42 (50% detectable) 
MIP-1β <3.2 – 1510 (70% detectable) <0.64-20 (81% detectable) 
TNFα <3.2 – 406 (30% detectable) <0.64-193 (75% detectable) 
IL-18 ** 36.1 – 258 (n=46) <0.64-335 (89% detectable) 
*All human cytokine concentration data except IL-18 provided by Millipore as obtained from 
their Milliplex MAP Human Cytokine/Chemokine 42-plex panel (catalog number MPXHYTO-
60K) [73]. 
**Human IL-18 concentration data provided by R&D Systems as obtained by their IL-18 
Quantikine ELISA 
 
Figure 8: The percent of samples tested from humans and NHPs that are within the detectable 
ranges for the rejected cytokines. 
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Figure 9 shows the distribution of all 36 animals for each rejected cytokine.  Points 
representing samples outside the limit of detection are differentiated by symbol shape 
(open circles).  For these box-and-whisker plots, the top of the box represents the top 75th 
percentile, the middle line is the median, the bottom of the box represents the bottom 25th 
percentile and the whiskers extend to the minimum and maximum (excluding outliers); 
outliers are shown beyond the reach of the maximum whiskers and were calculated as 
being ≥ 1.5 times the IQR outside the IQR.   
 
Figure 9: Cytokine concentration distribution for rejected cytokines.  
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 Appendix E: Complete NHP Cytokine Results and Fold Change Data 
 
The cytokine concentrations observed for all animals are presented here, in Table 18.  For 
animals that had more than one sample tested an average was taken to determine the 
cytokine value for that animal.  Highlighted cells indicate outliers (as determined using 
the Tukey method). 
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 Table 18: Cytokine concentration results for each NHP tested (averages calculated for animals with more than 1 sample tested). Outliers are 
shaded and were determined by the Tukey method (≥ 1.5 times the IQR above the IQR).  
Animal 
ID
Avg of how 
many samples Sex
Age 
(Days)
Weight 
(Kg) G-CSF GM-CSF IFNγ IL-1β IL-1ra IL-2 IL-4 IL-5 IL-6 IL-8
IL-12/23 
(p40) IL-13 IL-15 IL-17
1 1 M 2194 6.6 <0.64 <0.64 0.7 <0.64 <0.64 13.3 <0.64 <0.64 <0.64 8,468 189.2 1.4 3.8 <0.64
2 2 F 2331 6.4 18.4 209.8 41.1 <0.64 <0.64 8.0 <0.64 0.7 <0.64 622 240.3 1.6 4.5 0.9
3 1 M 2018 7.1 <0.64 <0.64 9.6 <0.64 <0.64 26.3 <0.64 2.5 1.0 2,175 261.0 1.5 10.5 <0.64
4 1 M 1700 4.5 3.1 16.9 1.3 <0.64 <0.64 7.1 <0.64 <0.64 5.6 4,126 72.7 4.0 7.3 <0.64
5 1 M 2296 5.6 6.6 3.3 2.5 <0.64 <0.64 16.6 <0.64 <0.64 21.6 2,753 234.0 12.6 4.5 42.2
6 1 M 1954 6.7 12.8 1.1 1.4 <0.64 3.2 22.2 <0.64 <0.64 <0.64 2,541 56.8 1.9 5.9 <0.64
7 1 M 1968 5.1 3.2 <0.64 <0.64 <0.64 <0.64 22.9 <0.64 <0.64 <0.64 8,215 127.4 1.7 2.7 <0.64
8 2 F 2345 5.3 11.7 647.4 46.4 <0.64 13.2 11.2 <0.64 <0.64 2.7 1,101 473.1 3.1 <0.64 <0.64
9 1 M 2176 5.9 5.7 <0.64 <0.64 <0.64 <0.64 1.3 <0.64 1.9 <0.64 3,432 87.8 2.2 <0.64 <0.64
10 2 M 1788 5.9 8.1 18.7 <0.64 <0.64 <0.64 2.9 2.6 <0.64 <0.64 4,863 56.8 2.9 1.4 1.3
11 3 M 1697 5.7 3.8 26.2 1.1 <0.64 <0.64 8.8 1.9 <0.64 <0.64 5,334 53.4 3.9 3.5 0.8
12 7 M 2133 5.9 6.0 34.3 7.1 <0.64 28.3 6.5 <0.64 <0.64 6.6 2,075 124.9 1.7 5.7 2.0
13 2 M 1655 4.7 8.8 29.5 3.5 <0.64 <0.64 6.6 <0.64 <0.64 <0.64 1,746 106.9 1.8 3.2 0.7
14 1 M 2119 5.8 <0.64 <0.64 1.4 <0.64 <0.64 5.9 <0.64 <0.64 <0.64 647 107.8 <0.64 6.1 <0.64
15 1 M 2019 3.7 LBC 11.2 1.0 <0.64 <0.64 5.8 <0.64 1.2 11.9 5,063 69.6 2.7 2.6 1.1
16 1 M 1752 5.3 <0.64 23.6 10.8 <0.64 <0.64 3.7 <0.64 <0.64 6.5 701 104.8 <0.64 4.3 5.0
17 1 M 1659 5.6 2.9 122.3 12.3 <0.64 0.7 7.1 <0.64 <0.64 1.2 1,991 151.7 6.4 7.9 <0.64
18 2 M 1373 3.9 5.0 44.7 3.3 <0.64 <0.64 6.8 <0.64 2.4 <0.64 6,191 80.3 2.9 5.6 1.1
19 1 M 1876 3.6 <0.64 0.7 1.0 <0.64 <0.64 4.8 <0.64 0.7 <0.64 606 45.3 1.5 2.2 <0.64
20 1 M 1954 7.3 <0.64 <0.64 <0.64 <0.64 <0.64 9.5 <0.64 <0.64 <0.64 1,263 27.9 <0.64 1.1 <0.64
21 1 M 2041 4.5 4.1 <0.64 4.7 <0.64 <0.64 13.7 <0.64 <0.64 <0.64 442 83.9 <0.64 6.2 <0.64
22 1 M 2193 7.9 LBC <0.64 <0.64 <0.64 <0.64 27.0 <0.64 <0.64 <0.64 3,840 73.6 2.6 3.1 <0.64
23 1 M 2214 6.0 1.5 2.1 47.9 3.5 16.6 32.8 <0.64 <0.64 4.2 442 584.4 1.9 18.4 <0.64
24 1 M 1976 6.4 <0.64 <0.64 0.8 <0.64 <0.64 3.0 <0.64 4.7 <0.64 271 115.3 <0.64 0.9 <0.64
25 3 M 1782 4.4 5.3 4.7 1.4 <0.64 <0.64 10.1 <0.64 1.4 7.6 3,300 122.2 4.7 2.8 0.9  
 
 
 
131 
 
 Table 18 Continued 
Animal 
ID
Avg of how 
many samples Sex
Age 
(Days)
Weight 
(Kg) MCP-1 MIP-1β MIP-1α sCD40L TGFα TNFα VEGF IL-18
1 1 M 2194 6.6 211.8 <0.64 <0.64 >10000 3.1 4.1 4.7 16.2
2 2 F 2331 6.4 359.2 7.3 8.1 5,125 12.8 2.0 42.8 24.4
3 1 M 2018 7.1 462.2 0.7 <0.64 >10000 5.6 8.9 <0.64 16.9
4 1 M 1700 4.5 439.9 0.7 10.0 7,631 14.7 <0.64 11.9 78.7
5 1 M 2296 5.6 321.2 0.6 256.3 188 8.6 0.8 1798.1 106.3
6 1 M 1954 6.7 447.1 4.3 5.4 9,633 4.3 2.1 4.3 25.2
7 1 M 1968 5.1 294.5 <0.64 <0.64 >10000 5.0 2.6 4.7 53.8
8 2 F 2345 5.3 285.9 11.7 7.1 3,923 15.0 82.2 318.7 74.9
9 1 M 2176 5.9 275.4 1.1 3.9 513 2.6 7.7 <0.64 30.0
10 2 M 1788 5.9 246.1 1.1 1.6 5,279 6.3 <0.64 73.9 102.9
11 3 M 1697 5.7 488.7 2.7 4.5 5,758 13.2 1.1 10.9 145.4
12 7 M 2133 5.9 631.5 4.0 9.6 3,512 13.7 9.3 7.9 46.0
13 2 M 1655 4.7 419.1 2.6 13.9 5,185 8.3 1.4 9.5 30.7
14 1 M 2119 5.8 398.5 1.0 <0.64 3,995 4.0 <0.64 <0.64 <0.64
15 1 M 2019 3.7 356.2 2.8 7.7 10,978 3.5 3.7 228.5 67.3
16 1 M 1752 5.3 350.2 <0.64 54.2 3,138 22.8 2.8 9.8 8.0
17 1 M 1659 5.6 281.2 3.8 7.5 4,750 7.2 14.8 35.3 109.3
18 2 M 1373 3.9 575.9 1.7 14.6 6,357 16.7 3.6 5.4 94.1
19 1 M 1876 3.6 170.1 1.5 4.3 475 6.6 <0.64 <0.64 3.1
20 1 M 1954 7.3 200.0 <0.64 4.6 1,693 14.5 <0.64 <0.64 <0.64
21 1 M 2041 4.5 102.4 <0.64 5.9 5,169 4.5 0.7 7.3 <0.64
22 1 M 2193 7.9 336.3 <0.64 2.6 >10000 3.8 <0.64 12.2 36.0
23 1 M 2214 6.0 293.1 12.4 17.8 6,762 10.4 38.6 201.8 81.4
24 1 M 1976 6.4 338.2 <0.64 0.8 10,829 6.1 14.9 <0.64 <0.64
25 3 M 1782 4.4 462.3 7.6 12.2 7,600 7.8 1.2 28.6 158.3  
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 Table 18 Continued 
Animal 
ID
Avg of how 
many samples Sex
Age 
(Days)
Weight 
(Kg) G-CSF GM-CSF IFNγ IL-1β IL-1ra IL-2 IL-4 IL-5 IL-6 IL-8
IL-12/23 
(p40) IL-13 IL-15 IL-17
26 2 M 1794 5.1 0.9 19.7 6.4 <0.64 <0.64 7.6 <0.64 4.7 1.5 1,599 74.9 2.9 1.5 <0.64
27 1 M 1657 4.7 3.6 7.1 3.3 <0.64 <0.64 4.8 LBC <0.64 3.0 2,408 24.4 2.3 2.9 1.0
28 1 M 1768 5.1 3.0 43.5 <0.64 <0.64 <0.64 77.8 <0.64 <0.64 <0.64 8,973 136.6 <0.64 1.7 0.9
29 2 M 1918 5.1 6.8 50.5 2.7 <0.64 <0.64 10.0 <0.64 <0.64 <0.64 1,593 117.9 2.7 1.6 0.7
30 1 M 1865 4.0 3.9 101.1 16.4 2.2 <0.64 11.8 <0.64 15.4 5.5 943 146.0 3.0 13.8 <0.64
31 1 M 1812 4.2 <0.64 13.8 1.1 <0.64 <0.64 6.6 <0.64 <0.64 1.2 1,281 74.0 1.7 5.4 <0.64
32 1 M 1248 4.0 8.7 141.4 4.1 <0.64 <0.64 12.5 2.8 <0.64 <0.64 13,345 46.1 11.1 1.0 2.4
33 1 M 1881 3.9 <0.64 19.2 3.8 <0.64 <0.64 1.8 <0.64 <0.64 1.2 556 60.0 1.4 <0.64 0.7
34 2 M 2179 4.2 <0.64 50.4 <0.64 <0.64 35.9 9.1 <0.64 <0.64 7.4 1,460 76.1 6.4 3.3 6.3
35 1 M 1854 5.1 6.8 68.9 97.6 <0.64 6.0 17.6 <0.64 <0.64 <0.64 454 222.3 5.1 13.2 1.1
36 1 M 1922 4.8 13.2 6.6 1.2 <0.64 <0.64 6.1 <0.64 <0.64 <0.64 2,150 57.8 6.3 5.7 4.7  
 
Animal 
ID
Avg of how 
many samples Sex
Age 
(Days)
Weight 
(Kg) MCP-1 MIP-1β MIP-1α sCD40L TGFα TNFα VEGF IL-18
26 2 M 1794 5.1 335.4 2.4 20.7 4,448 3.3 6.7 17.8 93.4
27 1 M 1657 4.7 304.8 2.4 11.3 4,054 12.0 <0.64 5.2 38.2
28 1 M 1768 5.1 602.2 20.3 18.2 4,038 8.5 5.5 32.4 102.3
29 2 M 1918 5.1 505.6 2.7 5.1 3,123 7.0 3.6 11.2 81.6
30 1 M 1865 4.0 429.8 6.3 10.6 2,606 22.3 17.2 4.7 10.4
31 1 M 1812 4.2 542.4 1.2 14.8 4,675 11.3 <0.64 5.2 22.0
32 1 M 1248 4.0 474.2 7.5 11.4 4,787 20.2 4.5 53.6 334.7
33 1 M 1881 3.9 238.7 1.5 <0.64 1,673 2.4 2.8 <0.64 7.1
34 2 M 2179 4.2 380.3 7.4 37.3 3,502 22.0 1.1 344.7 39.7
35 1 M 1854 5.1 142.7 4.8 32.7 8,861 36.1 193.2 38.6 127.5
36 1 M 1922 4.8 242.8 8.3 15.7 8,120 47.4 <0.64 16.3 116.6  
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In this cohort of 36 animals, 11 animals had multiple samples tested and of those 11, 
eight animals had only two samples tested.  In order to provide an analysis of intra-
animal variability, the fold change of each cytokine was calculated in each animal with 
multiple observations.  The fold change is calculated by dividing the highest 
concentration by the lowest concentration. A result of 1.0 indicates no change.  If more 
than two observations were included in the fold-change-analysis, the highest and lowest 
observations were used in calculations and if censored data were included, it was changed 
to half the detection limit (0.32 pg/mL rather than <0.62 pg/mL).  To evaluate the overall 
changes rather than the direction of change (increased or decreased concentration) from 
initial to final sample, the highest concentration was always divided by the lowest 
concentration so that all results are reported as fold changes of ≥ 1.0.  These data are 
presented in Table 19 for the accepted and marginal cytokines, while Table 20 shows 
these data for the rejected cytokines. Animal E is represented twice in Tables 19 and 20, 
as E1 and E2.  This animal had seven total samples tested (represented as E1), three of 
which were collected on the same day then tested in a single assay (represented as E2).  
The average variability for the 15 accepted and marginal cytokines within a day for this 
animal was a 2.4 fold change, compared to the average fold change for all animals of 2.6 
in these same 15 cytokines.  This supports the idea that the observed intra-animal 
variability may not be due to changes in health status but perhaps are part of normal, 
daily secretion patterns.  Additional studies are needed to define this variability.  
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 Table 19: Fold change data for each of the 11 animals with more than 1 sample tested over time in the accepted and marginal cytokines.  
Animal A (n=2) 
B 
(n=2) 
C 
(n=3) 
D 
(n=3) 
E1 
(n=7) 
E2 
(n=3) 
F 
(n=2) 
G 
(n=2) 
H 
(n=3) 
I 
(n=2) 
J 
(n=2) 
K 
(n=2) Average 
G-CSF 1.3 1.0 1.3 1.1 5.0 1.7 2.2 1.2 2.5 1.8 1.7 1.0 1.8 
IFNγ 2.2 1.3 1.0 1.3 3.6 1.4 1.9 1.3 1.7 1.5 1.1 3.5 1.8 
IL-4 3.1 1.0 16.0 1.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 3.3 2.6 
IL-2 3.4 1.2 1.1 2.3 2.6 2.1 1.2 2.0 1.2 1.5 1.1 2.1 1.8 
IL-5 4.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 2.1 29.1 1.0 1.0 3.7 
IL-6 1.0 2.3 1.0 1.0 1.0 1.0 1.0 1.0 5.9 4.0 1.0 46.2 5.5 
IL-8 2.1 1.1 1.3 1.6 7.7 3.0 1.6 1.0 1.8 1.6 1.2 1.1 2.1 
IL-12/23 
(p40) 2.0 1.9 1.2 1.7 2.9 1.2 1.8 1.3 1.4 1.2 1.1 1.1 1.6 
IL-13 1.2 1.0 1.8 2.5 2.2 1.3 1.1 1.3 1.5 1.5 1.0 20.0 3.0 
IL-15 1.4 1.0 2.5 1.6 3.0 2.1 3.3 2.9 2.3 2.4 1.4 10.4 2.9 
MCP-1 1.6 1.2 1.2 2.0 2.9 2.9 1.2 2.0 1.7 2.0 1.1 1.2 1.8 
MIP-1α 1.3 1.4 9.7 2.0 3.7 1.2 1.2 1.8 1.7 1.6 1.4 7.0 2.7 
sCD40L 1.1 1.0 1.1 1.3 10.5 10.5 1.5 1.3 1.4 2.2 2.5 2.1 3.0 
TGFα 1.1 1.8 1.4 2.3 4.9 2.1 2.1 1.1 6.3 1.6 2.4 4.7 2.2 
VEGF 1.7 1.3 2.1 2.2 5.4 3.5 1.1 1.5 2.9 1.2 1.0 8.6 2.5 
Average 1.9 1.3 2.9 1.7 3.8 2.4 1.6 1.4 2.4 3.6 1.3 7.6 2.6 
 
Table 20: Fold change data for each of the 11 animals with more than 1 sample tested over time in the rejected cytokines. 
Animal A (n=2) 
B 
(n=2) 
C 
(n=3) 
D 
(n=3) 
E1 
(n=7) 
E2 
(n=3) 
F 
(n=2) 
G 
(n=2) 
H 
(n=3) 
I 
(n=2) 
J 
(n=2) 
K 
(n=2) Average 
GM-CSF 4.7 1.1 3.5 8.2 14.6 1.5 2.0 4.8 1.3 2.0 1.1 56.3 8.4 
IL-1ra 3.8 1.4 1.0 1.0 30.6 8.1 1.0 1.0 4.5 1.0 1.0 224.4 23.2 
IL-1β 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
IL-17A 1.3 1.6 1.8 1.7 4.7 1.4 1.5 2.7 1.1 1.0 1.5 11.0 2.6 
MIP-1β 1.2 1.4 6.7 2.5 5.6 1.3 1.4 2.7 2.8 2.2 2.5 1.9 2.7 
TNFα 1.3 1.8 1.0 1.3 2.9 1.2 8.8 1.0 3.1 9.2 1.1 7.0 3.3 
IL-18 2.6 1.1 2.2 1.6 58.5 3.1 1.4 1.2 1.0 1.2 1.1 6.1 6.7 
Average 2.2 1.3 2.5 2.5 16.8 2.5 2.4 2.0 2.1 2.5 1.3 44.0 6.9 
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